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ABSTRACT OF THE DISSERTATION 
Application of Genomic Technologies to Study Infertility  
by 
Nicholas Rui Yuan Ho 
Doctor of Philosophy in Biology and Biomedical Sciences 
Computational and Systems Biology 
Washington University in St. Louis, 2016 
Donald Conrad, Chair 
 
An estimated one in eight couples in the United States are diagnosed with infertility. There is a 
significant genetic contribution to infertility, with estimates of heritability ranging from 0.2 to 
0.5. We know surprisingly little about the genetic causes, with only slightly more than a hundred 
genes known to cause human infertility. I have been translating recent advances in genomics to 
study infertility in a more efficient manner, in order to improve our knowledge of the genetic 
causes. By using high throughput genomics and proteomics datasets from other groups, I was 
able to feed that into a machine learning algorithm to predict novel fertility function genes. 
While not perfect, this computational model performs comparably to other publish prediction 
models. In order to test the top predicted fertility genes I also developed an experimental 
technique to simultaneously screen up to hundreds of genes for spermatogenesis function in vivo 
in mice. This method is based off of RNAi, and I was able to benchmark its performance to 
demonstrate that it performed comparably to other benchmarked RNAi screens in flies. I then 
used this method to test the top 26 predicted spermatogenesis genes and showed that most of 
them (24/26) have an important role in spermatogenesis. Using this technique, other groups can 
x 
screen genes for spermatogenesis function in a fraction of the time and cost compared to the 
traditional approach of generating knockout mouse lines. Finally, I describe the progress I have 
made in using genetic engineering to rescue spermatogenesis in mice. By analyzing the missteps 
I have made in delivering constitutively expressed transgenes and CRISPR genes into mouse 
testes, I describe the probably reasons for my failure and how to implement future experiments to 
get more success.  
1 
Introduction 
Application of genomic technologies to study infertility 
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Infertility is defined as the inability of a couple to achieve pregnancy after a year or more of 
regular unprotected sexual intercourse. This reproductive disease presents its phenotype as a 
couple, but the cause may be found in either partner. Approximately half of the cases of 
infertility are attributed to the male and half to the female partner in the couple. 
In its 2014 infertility white paper, the CDC reported that 12-18% of couples and 9% of men are 
infertile in the United States
1
. Infertility is also highly heritable, with heritability estimates 
ranging from 0.16 to 0.81, with a mean of around 0.3
2
. When looking specifically at male 
infertility, male relatives of couples treated with intracytoplasmic sperm injection were found to 
have higher rates of infertility than the general population
3
, and up to 10% of cases of 
azoospermia are clinically attributable to Y chromosome microdeletions in typical populations of 
European ancestry
4,5
. Numerous physiological systems are required for the maintenance of 
human fertility and genetic studies in mice and humans have played a major role in their 
dissection. Genes are now known to be involved in the proper information  of  male  and  female  
gonads  and  genitalia, neuroendocrine  control  of  gonadal function, paracrine regulation of 
gamete development, fertilization and implantation
6
. In total, the data suggests there is a 
significant genetic component to infertility. 
Given its high prevalence, surprisingly little is known about the genetic causes of this disease in 
humans. To date only a small handful of loci have been identified as definitively involved in 
human fertility, and these genes explain only a small proportion of the heritability of fertility
7–11
. 
This is due to the traditional method of infertility gene ascertainment, phenotyping knockout 
mice, which is time-consuming, low-throughput, and expensive. Ongoing generation and 
analysis of mouse mutants from places like Knockout Mouse Project and various other 
investigators have slowly produced a larger list of gonad-essential genes, but this is still far from 
3 
comprehensive. As high-throughput DNA sequencing moves to the clinic, there will be a deluge 
of data generated about human infertility. However interpreting variations across the whole 
genome of infertile patients is a difficult problem at best and it will be almost impossible to 
verify all candidate infertility genes via traditional methods. 
My research has been focused on increasing the efficiency of discovering candidate genes and 
verifying their function in-vivo. To help identify infertility genes in patients, I will show that I 
can use available high throughput data about human genes that have been generated by other 
groups to come up with a set of infertility candidate genes based on co-regulation, expression 
and protein-protein interactions. I will also demonstrate a new experimental method which can 
be used to screen a panel of genes in-vivo in mouse testis. This method can be used as a primary 
screen for male infertility genes that are identified in humans, reducing the cost and speeding up 
the verification process. Finally I discuss the work I have performed using genetic engineering to 
attempt to rescue spermatogenesis in mice. 
  
4 
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Chapter 1 - Introduction 
There has been a recent explosion in the amount of genomewide genomic data being generated 
on hundreds of human and mouse cell types, including germ cells, much from the Encyclopedia 
of DNA Elements Consortium (ENCODE)
1,2
. Gene expression, histone modifications, and 
methylation have all been assayed on bulk gonadal tissue, and in some cases, purified germ cells. 
I hypothesized that since known fertility genes work in a small set of pathways, I can 
computationally identify genomic features among genomic high throughput data that distinguish 
“fertility genes”. All genes in the genome with similar features are likely to be similarly 
regulated and are probably working in the same pathways. These genes are likely to also cause 
fertility problems when mutated. 
 
To accomplish this I apply a technique known as “supervised learning”, creating a model for 
classifying unlabeled objects from studying pre-existing labeled, training data. In the simplest 
implementation, the purpose of the classifier is to place unlabeled objects into one of two groups, 
say, “positive” and “negative”. This method has had good results for well-studied diseases with a 
large set of known causative genes in humans
3,4
 and various tools have been made which use 
single features to define similarity amongst genes, ranging from disease ontology terms to 
protein structure and tissue-specific expression
5–8
.  
 
Since the genomic feature information fed to the model greatly influences the results, I had to 
build my own tool since the existing tools can only use a small subset of the current high 
throughput data. I explored the use of a diverse set of high-throughput genomic data types, 
including protein-protein interaction networks, gene co-expression networks, tissue and cell 
7 
type-specific expression levels, epigenetic marks, and gene conservation. In the process I 
obtained over 30 published sequencing-based genomic datasets from human and mouse and 
reprocessed them with a uniform pipeline to ensure comparability.  
 
The other key factor that determines accuracy is the size and curation of the training set used to 
train the model. Larger gene sets that are more specific to a given phenotype improve the 
performance of supervised learning models. In the case of infertility, there is a relatively small 
list of genes that have been definitively shown to cause disease in humans which work in various 
pathways. To get around this issue, I used data from mouse knockout lines to augment my 
training datasets.  
 
I first tested my approach on the better annotated mouse genome, classifying genes in general 
categories like “reproductive” as well as focusing on specific physiological processes such as 
“meiosis arrest” or “ovulation” for classification. I was able to validate that my classifier 
performs at a comparable level to other previously published models. In general, there were 
improvements in classification accuracy for the more specific phenotypes, as quantified by the 
area under the receiver-operator-characteristic curve (AUC). I then applied my model to the 
human genome to classify genes by using the small set of known human fertility genes. 
 
The main product of this work is a list of quantitative predictions about the relevance of each 
gene in the human and mouse genome to reproductive function. These quantitative summaries 
can be used as a research resource for hypothesis generation, say in the design of experiments, or 
the interpretation of human genetic data. I show some uses of the quantitative predictions by 
8 
showing how they can be used to improve detection and interpretation of pathogenic copy 
number variants (CNVs) in genomewide association studies of gonadal function. 
 
One other significant result of my work is to provide some insight into the relative importance of 
the complex and rapidly growing genomic data on reproductive cell types. By evaluating a large 
amount of genomic data side-by-side, I was able to make precise statements about the 
information generically relevant to infertility contained in each of these data types. This is a first 
attempt at what will be an increasingly visible and routine problem for reproductive biologists: 
how to computationally integrate human genetic analysis, model organism research, and 
genomic data to precisely predict the reproductive consequences of mutation.  
 
Figure 1.1 Overview of the study.  
I set out to assess the utility of functional genomic data for predicting the identity of genes 
relevant to mammalian fertility using a machine learning approach. I obtained and reprocessed 
over 30 high-throughput functional genomic datasets from mouse and human, and used these to 
annotate all genes in the mouse and human genomes, respectively. Using extensive phenotyping 
data from Jackson Labs Mouse Genome Informatics (MGI), I generated a negative training set 
of genes which were highly unlikely to be related to mammalian fertility. I then created multiple 
positive gene training sets of genes known to disrupt mammalian fertility, identified in either 
mouse or human. I combined each positive gene training set with the negative gene training set 
and used these to create phenotype-specific gene classifiers using linear Discriminant analysis. 
The accuracy of each classifier was then evaluated using standard statistical approaches.  
9 
Chapter 1 - Results 
I tried various modeling frameworks before settling on using Linear Discriminant Analysis 
(LDA) for my supervised learning classifier. LDA has worked well in the past to generically 
predict human haploinsufficient genes
9
. Since LDA uses a linear combination of genomic 
features to make its predictions, the features with the largest separation between training groups 
are also the ones weighted most when classifying the test set. This provides me with the 
advantage of being able to consider many different data types, picking only the most informative 
genomic features (Larger difference = more informative). In this study I considered numerous 
genomic features such as stage-specific and tissue differential RNA expression data, locus 
conservation between species and, protein-protein interactions (PPI), but only picked the best 3-4 
to actually make any given model prediction. 
 
To ensure that the data generated by different experiments were comparable, I downloaded the 
raw sequencing reads for the ChIP-seq and RNA-Seq experiments and remapped and quantified 
them using the same pipeline. PPI scores were generated by determining proximity to different 
gene sets such as reproductive genes and cancer genes (Methods). 
 
There are two inputs for an LDA model. Apart from the genomic features that the LDA model 
will use to calculate variance, it also needs examples of the “positive” and “negative” genes. 
Because the ideal, large and well-curated, fertility training set is unavailable for humans, I 
performed my investigations with various gene sets (Figure 1.1). This resulted in predictions of 
sets of genes involved in different reproductive processes, ranging from a category as broad as 
“fertility” to something as narrow as “abnormal ovulation without superovulation”.  I have 
10 
picked the models with the best results to present here, but I discuss all the models I tested in the 
supplement. 
 
A popular measurement of the accuracy of a classification model is the Area Under the Receiver-
Operator-Curve (AUC), where a larger AUC means the model has a better trade-off between 
accuracy and specificity. The maximum AUC for a two-category model is 1 (perfect prediction) 
and the minimum is 0.5 (random guessing). For each set of predictions I used 10-fold cross 
validation to test the precision and sensitivity of the LDA models. This method essentially leaves 
out 10% of the training set for testing and repeats it ten times, leaving out different genes each 
time, in order to determine how much error there is in the precision and sensitivity 
measurements. 
 
MGI genes on mouse genome model 
I first constructed models for three broad categories of genes: fertility, male fertility, and female 
fertility, using mouse genetic and genomic data.  The AUC for the gender aspecific model was 
0.711, 0.741 for the male specific model, and 0.738 for the female specific model for the 15,212 
genes tested in the mouse genome (Figure 1.2).  
 
In principle, genes involved in a narrow biological process should be more tightly co-regulated 
and co-evolving than a set of genes involved in diverse processes; thus I reasoned that genes 
involved in narrowly defined processes should be easier to model and predict. Based on the 
phenotype observed in knockout mice, I picked 12 of them that had at least 50 different genes 
implicated. I then characterized these models on the mouse genome. (Methods) 
 
11 
Figure 1.2: Model performance benchmarks for fertility gene sets 
Each figure shows the receiver operator characteristic (ROC) curves corresponding to 
classifiers based on functional genomic data derived from mouse (left) or human (right) 
genomes. The negative training set for each classifier is always the same set of MGI null genes.  
 
 
The subcategory models all had better ROC curve AUC than the more general infertility models, 
but their precision recall curve AUCs were not as good (Figure 1.3). Among these models I 
ended up characterizing the results of two, male meiosis arrest and abnormal female meiosis, 
because they were the only ones that performed better than the more general fertility models in 
both metrics. 
 
Among all the genomic features for the mouse models that I tested (Figures 1.S1-1.S3, 1.S9-
1.S20), I found that PPI with genes in the positive set and gonad RNA expression were the most 
important ones. Some histone modification marks (H3K27ac) also proved to be helpful in 
building the male infertility prediction models (Figure 1.4). 
12 
 
Figure 1.3: Model performance vs training set size 
For each classification model, I plotted the Precision-recall AUC (AUPRC) versus Receiver 
Operator Characteristic AUC (AUROC) as two measures of model performance. I fit trend lines 
to each set of points using loess regression, with AUPRC in red and AUROC in blue. In general, 
AUROC decreases with increasing positive training set size, while AUPRC increases. 
 
 
Human genetic studies’ genes on human genome model 
Because my approach was working for the large and small mouse derived training sets I 
reasoned that it may also work just as well with the smaller set of fertility genes implicated in 
humans. I combined male and female infertility genes that work in various pathways from 
13 
review articles to generate four positive training sets (Methods). Because it was difficult to find 
a list of genes proven not to cause fertility problems in humans, I translated the MGI null gene 
set into conserved human genes and used this as the negative training set. 
 
Figure 1.4: Selected feature Importance to each model 
These show the relative importance of the genomic features used to construct the nine models 
presented towards the model predictions. I show a subset of all the features that I tested, 
presenting only the ones actually used in the model(s). All the other features are presented in the 
supplement. 
 
I got better performance for these models compared to the mouse models, with AUCs of 0.913 
for the general fertility model, 0.946 for the male specific model, and 0.927 for the female 
14 
specific model for the 17,758 genes tested in the human genome. The non-obstructive 
azoospermia model also had a good AUC of 0.95 (Figure 1.2). 
 
There were fewer human genomic features available compared to mouse (Figures 1.S4 – 1.S7), 
and among the ones I tested PPI with genes in the positive set was the most important. Other 
useful features were gene conservation and gonad RNA expression, but to a much smaller extent 
(Figure 1.4). 
 
LDA Model 
Predictive 
Score cutoff 
False 
Positive 
Rate 
Sensitivity Precision 
Positive 
Training 
Set Size 
Negative 
Training 
Set Size 
# 
Candidate 
Genes 
MGI reproductive set 
on mouse genome 
0.4906 0.05 0.211 0.557 999 
3,344 
558 
MGI male 
reproductive set on 
mouse genome 
0.3585 0.05 0.228 0.449 600 737 
MGI female 
reproductive set on 
mouse genome 
0.4492 0.05 0.247 0.402 458 402 
MGI male meiosis 
arrest set on mouse 
genome  
0.0225 0.05 0.609 0.2 69 867 
MGI abnormal female 
meiosis set on mouse 
genome 
0.00197 0.05 0.692 0.1385 39 876 
Human fertility genes 
on human genome 
0.1055 0.05 0.536 0.282 125 
3,406 
638 
Human male fertility 
genes on human 
genome 
0.0002303 0.05 0.612 0.193 67 592 
Human female fertility 
genes on human 
genome 
0.0355 0.05 0.516 0.158 62 696 
Human non-
obstructive 
azoospermia genes on 
human genome 
4.737 X 10-
32 
0.05 0.659 0.136 41 1030 
Table 1.1: Summary of prediction results for 9 reproductive gene classifiers 
This shows the benchmarks using different cutoffs for the Chi score produced by the functional 
gene prediction models. The predictive score cutoff tries to get close to a 5% false positive rate. 
We tested 15,212 genes in the mouse genome and 17,758 genes in the human genome. 
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Model predictions 
In order to produce a list of candidate genes likely to modulate fertility, I used a cutoff for the χ 
score produced by the LDA model, where any gene with a χ score greater than or equal to the 
cutoff is considered a candidate for being an important gene for reproduction. The cutoff for each 
model was chosen so that the resulting candidate gene predictions would have at most a 5% false 
positive rate (FPR). (Table 1.1) This created shortlists of candidate infertility genes numbering 
between 400 – 900 genes for the mouse genome and between 590 – 1030 genes for the human 
genome (depending on the phenotype).  
 
Using model predictions to improve identification of human fertility-associated CNVs  
A primary challenge in genomewide association studies is the identification of true disease-
associated variation amongst the background of millions of unassociated variants within a given 
set of individuals. One strategy for improving detection power is to test only those variants that 
have strong a priori evidence for contributing to the disease process, such as variants near genes 
expressed in the tissue(s) of interest. I sought to evaluate how my fertility gene predictions could 
be used to improve analysis of case-control data from cohort studies of gonadal function.  
 
First I took data generated from several cohorts of male and female gonadal dysfunction, as well 
as matched controls, previously used for genomewide association studies (GWAS). I found that 
an infertile patient had an odds ratio of 1.25 of having a deletion spanning any gene exon 
compared to a control individual. When I used my all-gender model gene predictions to consider 
only deletions spanning at least one exon of a candidate gene, the same patients had a slightly 
higher odds ratio of 1.48 than the controls. Finally when looking at the male human model 
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predicted infertility genes for the male cases and the female human model predicted infertility 
genes for the female cases, I found that cases had a much higher odds ratio of 2.31 of having a 
deletion in one of the predicted infertility genes than controls. (Table 1.2) 
 
I also looked at candidate genes that were deleted multiple times in either male or female cases 
alone, but not controls (Table 1.3). This produced a list of 14 patients in azoospermia and 2 
patients in primary ovarian insufficiency. Eight of the cases of azoospermia had deletions 
covering known male fertility genes (CDY1, CDY1B, DAZ1, DAZ2, DAZ3, DDX3Y, USP9Y), 
while 4 of them had deletions covering DMRT1 (2 of them also covered FOXD4). The last two 
patients had deletions covering PSG5. For the female cases with primary ovarian insufficiency, I 
found 2 patients with deletions covering PRL.  
 
Chapter 1 - Discussion  
The premise of this study was that high-throughput functional genomic data from mouse and 
human germ cells and tissues could be used to identify novel infertility genes. Ideally this would 
work by finding other genes that are regulated similarly or interact with known infertility genes, 
thus likely to work in the same molecular pathways. Because pathways are often the basis of 
genotype-phenotype mapping, I expect that disrupting the same pathway in different ways can 
produce correlated disease phenotypes. 
  
Are the genomic features that were ultimately most informative for my gene classifiers 
consistent with this hypothesis? It would appear so, given that the PPI distance to reproductive 
genes was consistently the most significantly separated genomic data features between the 
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positive and negative gene sets. Aside from PPI distance, 6 of the 8 most useful genomic features 
that I observed were based on germ cell or gonad gene expression levels, and only one was based 
on an epigenetic mark (Figure 1.5).  Genomic features derived from male tissues tended to be 
more informative across multiple models than genomic features derived from female tissues. 
This could reflect the fact that more high quality functional genomic data are available on 
specific developmental subpopulations in male gametogenesis compared to female 
gametogenesis. This is largely due to technical limitations in isolating and generating data from 
scarce cellular populations, and I expect that richer female functional genomic datasets will 
emerge with time and innovation.  Intriguingly, some genomic features derived from male 
gonads were also informative for predicting female infertility genes across a broad range of 
phenotypes, especially male germ cell and gonad expression levels. I interpret this as 
underscoring a common set of pathways that are involved in gametogenesis for males and 
females (probably beyond obvious shared processes such as meiosis).  
 
These results suggest that getting high resolution RNA expression of various germline cell types 
and gonads will be the best way to improve fertility gene predictions in both humans and mice. 
Furthermore, it looks like the RNA expression results that came from a pool of cells were more 
reliable than the single cell experiments, leading us to conclude that for single cell sequencing 
results to be useful it need to be repeated many times to get an accurate idea of the average cell 
expression. 
 
I evaluated my ability to predict genes involved in 15 mouse reproductive phenotypes and 4 
human reproductive phenotypes. Each predictive model produced an area under the ROC curve 
18 
in the range of 0.7 - 0.9 and area under the precision-recall curve of 0.2 - 0.4, numbers 
competitive with many other predictive models that have been reported for disease gene 
classification
3,6,7,9
. Interestingly, the gender specific models slightly outperformed the all-gender 
model, confirming that while there is a shared molecular basis for infertility in both genders (e.g. 
defects in meiosis), there are also unique pathways that contribute to fertility in each gender. 
 
Figure 1.5: Functional annotations contain both general and sex-specific information. 
Many of the functional annotations used to produce my classifiers are obtained from sex-specific 
germ cells. For the top 8 most informative features in my study, I show the relative importance of 
each feature to the performance of 7 male (blue) and 5 female (pink) classifiers, summarized as 
a box-and-whiskers plot of the –log10(P) scores for each feature. A higher –log10(P) score 
indicates that the feature better differentiates between the positive and negative training set 
genes. While features derived from male gonads were typically more sex-biased in their 
predictive power than features derived from female gonads, it is interesting to note that 
spermatogonial expression levels appeared to be equally useful for predicting genes involved in 
both male and female reproductive traits. 
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Since I used a standard cutoff of 5% false positive rate for all models to identify candidate 
infertility genes, the two measures of model performance I used were the sensitivity and 
precision. A high sensitivity means that the model was able to identify most of the known 
fertility genes among its identified candidate genes, giving you confidence that the model is 
reasonably comprehensive. A high precision means that there are more known fertility genes 
than non-fertility genes among all the predicted candidate genes, letting you trust that any given 
candidate gene is less likely to be a false positive.  
 
Sensitivity was negatively correlated to the size of the positive gene training set (Figure 5). This 
could be due, in part, to the method I use to get the smaller positive gene training sets, picking 
genes involved in a certain phenotype and thus similar pathways, making other genes in the 
small set of pathways easier to identify. However since the negative gene training set is much 
larger, it results in the unfortunate side effect of lower precision with shrinking positive training 
gene set sizes. The false negatives can be attributed to genes that affect fertility by external 
mechanisms (e.g. Insulin reduces fertility by causing diabetes) or genes that have few other 
genes annotated in their pathways. The false positives are most likely caused by noisy data such 
as spurious in-vitro protein-protein interactions with little biological function in-vivo. 
 
Even with the trade-off between precision and accuracy, I found that using the predicted 
infertility genes helped improve the odds ratio of cases versus controls in the human infertility 
studies (Table 1.2). This increase in the odds ratios show that my predictions are enriched for 
true infertility genes relative to a random selection of genes and that the gender-specific model 
predictions provide the best enrichment. 
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All-gender model scores Fisher’s exact test 
 Positive Negative p-value 1.64 X 10
-8 
Case 313 1,558 Odds ratio 1.475309 
Control 1,792 13,160 95% Confidence interval 1.289827 – 1.683816 
Gender-specific model scores Fisher’s exact test 
 Positive Negative p-value 2.2 X 10
-16 
Case 642 1,229 Odds ratio 2.307403 
Control 2,760 12,192 95% Confidence interval 2.075971 – 2.563118 
Deletion CNVs spanning genes Fisher’s exact test 
 Positive Negative p-value 3.663 X 10
-6 
Case 953 1,005 Odds ratio 1.250934 
Control 6,447 8,505 95% Confidence interval 1.136988 – 1.376255 
Table 1.2: Tests of association between gene-disrupting CNVs and infertility. 
Positive/negative status of case/control individuals was determined by taking the highest scoring 
gene in any CNV in the patient and judging based on the cutoffs determined in Table 1. The all 
gender model score uses the MGI reproductive set on human genome model score of the genes 
for both male and female cohorts. The gender specific model score uses the MGI male 
reproductive set on human genome model scores for the male cohort patients and the MGI 
female reproductive set on human genome model scores for the female cohort patients. 
Positive/negative status for the deletion CNVs spanning genes table was determined by whether 
the patient had any loss of copy number CNVs that span exons 
 
To highlight the best predictions, I chose the infertility genes that were deleted multiple times in 
the infertile patients across the case-control studies (Table 1.3). One such candidate is DMRT1, 
which was deleted in 4 different patients and is known to affect post-natal testis differentiation in 
mice
10
  and is associated with male infertility
11
. I also found PRL deleted in 2 primary ovarian 
insufficiency patients. Female knockout mice lacking PRL are also infertile (Males are fine)
12
, 
and overexpression of this gene cause many detrimental effects in humans including female 
infertility
13
. Finally, the last candidate gene that I highlight is PSG5, which was found to be 
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deleted in 2 different azoospermic men. This gene is not very well studied, and its homolog in 
mice (PSG22) does not have a knockout line created yet. PSG5 is expressed at high levels in the 
testis and is closely related to PSG1 which is highly expressed in the placenta. Further studies on 
this gene may show an important role in male fertility.  
 
Gene Recurrence Cohort 
All-gender 
chi-squared 
score 
Female  
chi-
squared 
score 
Male 
chi-
squared 
score 
CDY1 2 Azoo 0.999999 5.03 X 10
-3 
1 
CDY1B  Azoo 0.999998 1.36 X 10
-4
 1 
DAZ1  Azoo 1 5.75 X 10
-3
 1 
DAZ2  Azoo 1 3.47 X 10
-2
 1 
DAZ3  Azoo 0.125516 6.74 X 10
-7
 0.99982 
DDX3Y 5 Azoo 0.999991 1.59 X 10
-4
 1 
USP9Y 6 Azoo 1 8.81 X 10
-4
 1 
DMRT1 4 Azoo 1 0.999999 1 
PSG5 2 Azoo 0.640456 0.877 8.39 X 10
-4
 
PRL 2 POI 1 1 1 
 
Table 1.3: Candidate genes identified multiple times in gene-disrupting CNVs for infertility 
cohorts. 
Known infertility genes have their names bolded. 
 
This example shows application of my human gene predictions, providing a basis for prioritizing 
large candidate gene lists produced in GWAS for further experiments. In my own data, I have 
seen how these predictions can be used to hone in on one specific gene when investigating many 
genes deleted by a large CNVs (Figure 1.S22). Given that my available case-control studies’ 
genetic data was low resolution, this limited my analysis to large deletions. With the increasing 
commonplace use of exome sequencing for studies like this in the future it is likely that more of 
my predicted genes will be implicated. Furthermore, such data can be used to refine my 
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predictions by noting which of my predicted infertility genes have recurrent mutations more 
frequently in the cases than the controls.  
 
Functional genomic analysis of mammalian germ cells has historically been limited by the 
difficulty of working with mammalian gonadal tissue. These tissues are complex cellular 
mixtures, and large-scale isolation of specific cell types has been a rate-limiting step, especially 
from ovaries.  A primary barrier to follow-up of my large prediction sets is to apply a 
complementary high-throughput experimental system to test these predictions. To this end, I 
have been developing a method to perform multiplex shRNA screening directly in mammalian 
testis, and are in the process of using this to test over a hundred of my top candidates reported 
here.  My hope is that by tying together high-dimensional computational analysis of mammalian 
germ cells with novel high-throughput genomic assays in these same cells, I can help usher in a 
new era of functional genomics for mammalian reproductive biology. 
 
Chapter 1 - Methods 
Training gene sets 
To create the positive and negative trainings sets of mouse genes, I first used the Mouse 
Phenotypic Alleles database from Jackson Labs Mouse Genome Informatics (MGI) to make a 
list of unique genes where a knockout mouse had been made and phenotyped for at least one 
system. From this list, I extracted the genes with an observed reproductive system phenotype 
(MP:0005389) to make a reproductive positive training set gene list. For the negative training set 
gene list, I took all the other genes from the list that did not have a reproductive system 
phenotype and further filtered out the genes which caused embryogenesis (MP:0005380) and 
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abnormal survival (MP:0010769) phenotypes, but not the extended life span phenotype 
(MP:0001661) among the abnormal survival genes.  
 
To make the male reproductive training gene list I picked the genes shown to cause abnormal 
male reproductive morphology (MP:0001145) and physiology (MP:0003698) from the original 
positive training set gene list. Similarly I used the categories for abnormal female reproductive 
morphology (MP:0001119) and physiology (MP:0003699) to create my female reproductive 
training gene list. I also evaluated each of 12 subcategories: Abnormal female meiosis 
(MP:0005168), Abnormal endometrium morphology (MP:0004896), Abnormal spermiogenesis 
(MP:0001932), Azoospermia (MP:0005159), Decreased oocyte number (MP:0005431), Male 
meiosis arrest (MP:0008261), Oligozoospermia (MP:0002687), Teratozoospermia 
(MP:0005578), Abnormal ovulation without superovulation (MP:0001928), abnormal ovulation 
cycle (MP:0009344), male germ cell apoptosis (MP:0008280), and sperm physiology 
(MP:0004543), all taken from the same MGI database. 
 
MGI’s vertebrate homology table was used to translate the negative training sets into human 
conserved genes. Due to orthology relationships between mouse and human, the sizes of the 
human training genes set differed slightly from those of mouse, increasing from 3,344 genes in 
mouse to 3,406 genes in human. 
 
The human genetic studies’ derived positive training gene set was taken using Azoospermic/ 
Oligospermic gene set (AO) and female infertility gene set (POF) from some review articles
14–17
 
. This produced a list of 67 human male fertility genes and 62 human female fertility genes. 
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These lists were combined to produce a list of 125 human fertility genes. Finally the human male 
fertility gene list was curated for genes only found in non-obstructive azoospermia to produce a 
list of 41 genes. 
 
Gene similarity features 
All genomic feature data were normalized to a mean of 0 and a spread from -1 to 1 for the 
purposes of being able to compare different features. 
Expression properties 
ENCODE
1,2
 paired-end RNA-Seq reads were used for differential tissue expression. Mouse liver 
(ENCSR000AJU & ENCSR216KLZ), heart (ENCBS441FDF & ENCSR000BYQ), testis 
(ENCSR266ESZ & ENCSR000BYW) and ovary (ENCSR516UNF & ENCSR000BZC) were 
used. Human liver (ENCSR085HNI & ENCSR000AEU), heart (ENCSR000AHH & 
ENCSR635GTY), testis (ENCSR693GGB) and ovary (ENCSR046XHI) were used. Mouse 
spermatogenesis-specific expression was obtained from RNA-Seq paired end reads of two 
datasets, Soumillon (GSE43717)
18
 and Hammoud (GSE49624)
19
. Mouse and human oocyte 
RNA-Seq paired end reads were taken from Xue (GSE44183)
20
. 
All mouse RNA-Seq fastq files were mapped to the mm9 assembly while human RNA-Seq fastq 
files were mapped to the hg19 assembly. Alignment was performed using tophat2
21
 with the 
default values and gene expression was summarized using cuffnorm
22
 on the UCSC gene 
annotations to normalize across the datasets. I used cuffdiff with the default options to determine 
which genes are differentially expressed. 
Histone modification properties 
25 
H3K27ac, H3K27me3, H3K4me1 and, H3K4me3 histone modification marks for mouse 
spermatogenesis cell specific stages were taken from Hammoud (GSE49624). ENCODE was the 
source for the same histone modification marks for mouse testis. (ENCSR000CCU, 
ENCSR000CGB, ENCSR000CCV and ENCSR000CCW) 
I aligned the CHIP-Seq read to the mm9 assembly using Novocraft’s novoalign tool with its 
default options (http://www.novocraft.com). Following that, I used seqminer
23
 to map the reads 
+ -5kb around the transcription start site (TSS). I created several statistical summaries of the 
distribution of marks around the TSS including mean, standard deviation, kurtosis and skew. 
Network properties 
Protein-protein interactions (PPI) were collected from HPRD
24
, Reactome
25
, and STRING
26
 and 
integrated into a single PPI network by mapping interacting entities to HGNC symbols. 
Measures of network centrality (degree and betweenness) and modularity (cluster coefficient) 
were calculated using MCL
27
. Sum of weight of edges were calculated as a measure of proximity 
to a group of 'seed' genes as described previously
9
. Seed gene sets that I used to calculate scores 
included cancer, early development, haploinsufficiency and known reproductive genes that I 
supplied to the model. 
Gene properties 
The dN/dS, GERP scores, number of domains, number of exons, and length of domains for each 
gene were downloaded from EnsEMBL version 74. 
 
Linear Discriminant Analysis Model 
For each genomic feature, a given gene will have a score normalized to between -1 and 1. For 
this score, I can calculate the likelihood that a given gene belongs in either the positive training 
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set genes or the negative training set genes based on how similar it is to each group. In order to 
combine the information from multiple features together I used Linear Discriminant Analysis 
(LDA). The LDA approach assigns weights to each given feature such that the likelihood 
variance within each group is minimized and the variance between the positive and negative 
groups is maximized. Using the results from the LDA I then calculated the χ score for all genes 
which is a projection of the multidimensional data onto a one dimensional continuum. I can then 
pick a threshold χ score to divide the positive and negative groups, thus classifying the genes as 
either reproductively important (positive) or not (negative). 
To do 10-fold cross validation, I first split the positive and negative training sets into 10 random 
subsets, then training the model using 9 of those subsets, leaving 1 subset for testing. I then plot 
the false positive rate using the remaining negative subset and the false negative rate using the 
remaining positive subset at the various likelihood cutoffs for each possible subset. The Receiver 
Operating Characteristic (ROC) curve is generated by plotting the average false positive rate 
against the false negative rate of the 10 models. 
 
Human Infertility Gene Deletion Analysis 
I obtained existing Copy Number Variant (CNV) calls from men assayed in my previous study 
of spermatogenic impairment
28
. Using published, validated CNV calling pipelines, I generated 
new CNV calls from two female cohorts with extensive reproductive health history, GARNET 
and SHARE, both of which are components of the Women’s Health Initiative (WHI), using data 
obtained, with permission, from the Database of Genotypes and Phenotypes (dbGAP, Bethesda 
(MD): National Center for Biotechnology Information, National Library of Medicine). I used the 
extensive health history data available on each WHI subject to construct a diagnosis that I 
27 
believe approximates the clinical definition of primary ovarian insufficiency, resulting in a 
case/control classification for all WHI individuals.  
I performed a series of case-control association tests, testing for association between CNV carrier 
status and disease status. Patients were defined as “positive” for CNV carrier status if the carry at 
least one CNV that results in meeting one the following criteria, depending on the analysis: gene 
disrupting, fertility gene disrupting, or sex-specific fertility gene disrupting, where disrupting 
means that the CNV is deleted, not duplicated. A patient was otherwise classified as “negative” 
for CNV carrier status. I then built a 2X2 contingency table for the case-control status and ran a 
Fisher’s exact test. 
I then picked the sex-specific fertility gene disrupting CNVs that were found only in the cases 
and not the controls and extracted the candidate genes from them for further analysis. The 3 
genes that occurred more than once were discussed in the paper while the one-off genes were 
listed in a separately. 
 
Note: All supplemental tables (Table S1-S31) can be found in the supplement of the paper: 
Ho, N. R. Y., Huang, N. & Conrad, D. F. Improved detection of disease-associated variation by 
sex-specific characterization and prediction of genes required for fertility. Andrology 3, 1140–
1149 (2015). 
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Figure 1.S1: Data distribution of all features for MGI reproductive training set in the 
mouse genome 
The right plot shows the spread of the renormalized data when using positive and negative 
training sets. HI indicates positive training set genes and HS shows the distribution for negative 
control genes. The left bar plot shows how likely it is that the data came from the same 
distribution, where a higher –log10P signifies that it is more likely that the 2 features have 
different data distributions in the positive and negative training sets. The line in the left plot 
shows the percentage of the genome that the feature covers. The positive training set is the MGI 
reproductive gene set and the negative training set is the MGI null gene set. 
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Figure 1.S2: Data distribution of all features for MGI male reproductive training set in the 
mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
male specific reproductive gene set and the negative training set is the MGI null gene set. 
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Figure 1.S3: Data distribution of all features for MGI female reproductive training set in 
the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
female specific reproductive gene set and the negative training set is the MGI null gene set. 
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Figure 1.S4: Data distribution of all features for reproductive training set in the human 
genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the 
human fertility gene set and the negative training set is the MGI null gene set for genes that are 
conserved between mice and humans. 
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Figure 1.S5: Data distribution of all features for male reproductive training set in the 
human genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the male 
specific reproductive gene set and the negative training set is the MGI null gene set for genes 
that are conserved between mice and humans. 
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Figure 1.S6: Data distribution of all features for female reproductive training set in the 
human genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the 
female specific reproductive gene set and the negative training set is the MGI null gene set for 
genes that are conserved between mice and humans. 
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Figure 1.S7: Data distribution of all features for non-obstructive azoospermia training set 
in the human genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the non-
obstructive azoospermia gene set and the negative training set is the MGI null gene set for genes 
that are conserved between mice and humans. 
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Figure 1.S8: Model performance benchmarks without PPI 
Each figure shows the receiver operator curve for the LDA model classifying the test set genes 
correctly based on χ score cutoffs. Each LDA model has the PPI feature removed from the list of 
features used to generate the χ scores. The negative training set used is always MGI null genes. 
All MGI genes: Positive set is MGI male reproductive gene training set 
Female MGI genes: Positive set is MGI female reproductive gene training set  
Male MGI genes: Positive set is MGI reproductive gene training set 
Human Reproductive genes: Positive set is reproductive genes implicated by human GWAS 
studies 
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Figure 1.S9: Data distribution of all features for MGI abnormal female meiosis 
reproductive training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
abnormal female meiosis specific reproductive gene set and the negative training set is the MGI 
null gene set. 
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Figure 1.S10: Data distribution of all features for MGI abnormal endometrium 
morphology training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
abnormal endometrium morphology specific reproductive gene set and the negative training set 
is the MGI null gene set. 
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Figure 1.S11: Data distribution of all features for MGI decreased oocyte number 
reproductive training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
decreased oocyte number specific reproductive gene set and the negative training set is the MGI 
null gene set. 
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Figure 1.S12: Data distribution of all features for MGI abnormal ovulation cycle 
reproductive training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
abnormal ovulation cycle specific reproductive gene set and the negative training set is the MGI 
null gene set. 
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Figure 1.S13: Data distribution of all features for MGI abnormal ovulation reproductive 
training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
abnormal ovulation specific reproductive gene set and the negative training set is the MGI null 
gene set. 
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Figure 1.S14: Data distribution of all features for MGI male meiosis arrest reproductive 
training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
male meiosis arrest specific reproductive gene set and the negative training set is the MGI null 
gene set. 
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Figure 1.S15: Data distribution of all features for MGI azoospermia reproductive training 
set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
azoospermia specific reproductive gene set and the negative training set is the MGI null gene 
set. 
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Figure 1.S16: Data distribution of all features for MGI oligozoospermia reproductive 
training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
oligozoospermia specific reproductive gene set and the negative training set is the MGI null gene 
set. 
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Figure 1.S17: Data distribution of all features for MGI male germ cell apoptosis 
reproductive training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
male germ cell apoptosis specific reproductive gene set and the negative training set is the MGI 
null gene set. 
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Figure 1.S18: Data distribution of all features for MGI abnormal spermiogenesis 
reproductive training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
abnormal spermiogenesis specific reproductive gene set and the negative training set is the MGI 
null gene set. 
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Figure 1.S19: Data distribution of all features for MGI sperm physiology reproductive 
training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
sperm physiology specific reproductive gene set and the negative training set is the MGI null 
gene set. 
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Figure 1.S20: Data distribution of all features for MGI teratozoospermia reproductive 
training set in the mouse genome 
The figure is laid out the same way as Figure S1. Here, the positive training set used is the MGI 
teratozoospermia specific reproductive gene set and the negative training set is the MGI null 
gene set. 
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Figure 1.S21: Model performance benchmarks for mouse infertility subset phenotypes 
On the top are the figures for the receiver operator curve for the LDA model classifying the test 
set genes correctly based on χ score cutoffs. The negative training set used is always MGI null 
genes. On the bottom are the precision recall curves for the same LDA models. On the left are 
the specific infertility phenotypes that affect females while the male specific infertility phenotypes 
are on the right. 
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Figure 1.S22: Examples of finding candidate infertility genes in patient CNVs 
Each figure shows the scores for each gene in large CNVs found in a Nanjing azoospermia GWAS study. The top figure is a large 
deletion found in a control patient while the bottom three figures are for large deletions found in different case patients. This shows 
that while not every large CNV will have at least one potential candidate, in some CNVs there are candidate genes which are 
predicted to have a high likelihood of being causative for infertility. For example, MAPK3 in the second figure and LSS and S100B in 
the bottom figure. 
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Chapter 2 - Introduction 
Spermatogenesis requires the activation of many different pathways at various time points, 
varying from general processes like metabolism, cell cycle, meiosis, and transcription, to very 
specific functions like membrane capacitation and cell-cell recognition proteins
1,2
. Many of the 
pathways are even distinct from somatic cells despite having the same function
3
. Due to the 
complexity of this process, I expect that there should be numerous genetic defects that cause 
infertility. Pathogenic mutations that impair fertility are unlikely to be inherited (and thus 
recurrent), making it difficult to identify fertility genes via recurrent mutations in families. 
However as next generation sequencing becomes more affordable, Genome Wide Association 
Studies (GWAS) are helping to identify genes which are associated with infertility by finding 
recurrent mutations in unrelated individuals
4,5
.  
 
Unfortunately it is currently difficult to verify candidate fertility gene functions because the 
existing in vitro model systems for complete spermatogenesis are technically challenging to 
perform
6–8
. Generation of knockout mouse models has thus been the most popular tool to verify 
candidate pathogenic genes. This has been translated to humans to advance our knowledge and 
develop treatments for human infertility. However, costs a few thousand dollars and between 
months to years to characterize a single gene by generating a knockout mouse line. As large 
scale genomic studies become more commonplace, the gap between implicated and verified 
fertility genes will only get larger if this remains as the verification method of choice.  
 
To address this problem, I have developed a quick, simple, and inexpensive method to screen 
numerous genes simultaneously in vivo for spermatogenesis function. The basis for the method 
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lays in RNA interference (RNAi) screens, which are commonly used to efficiently elucidate gene 
function. This approach has been used in vitro
9,10
 in cell lines or in vivo
11–16
 in other tissues in 
mice to discover important genes for various different biological processes. 
 
The process of in vitro RNAi screens is relatively simple; cultured cells are transfected with the 
miRNA or RNAi expression construct using a highly effective transfection reagent (e.g. 
chemical, viral) and treated cells are then selected for a trait of interest (e.g. survival, response to 
stimulus). Following that, the cells are harvested and the RNAi in the cells with and without the 
selection pressure are quantified to determine the differences between them. To produce 
reproducible results it is important to have a sufficient percentage of cells infected. In vivo 
transfection rates tend to be orders of magnitude lower than in vitro systems for the same 
transfection reagent
17
. This leads to a trade-off between the number of biological replicates and 
the cost of the transfection reagent. To avoid the issue of low transfection rates, some groups 
have transfected certain cells in vitro and then transplanted them into recipient mice and 
performed selections in the xenografted models
13–16
. Spermatogonial stem cells have been 
transplanted into sterile donor testes to restore fertility in various species
18–20
. However this stem 
cell transplantation is a difficult technique to perform and there is a low number of unique stem 
cells that actually successfully transplant per mouse. This creates a bottleneck that makes cell 
transplantation inappropriate for a screening study, since screening relies on having a large 
number of independent transfection events in order to produce statistically significant results. 
Recently, a small number of studies have shown that one can use viruses to transfect mouse 
tissues in vivo with a sufficiently high transfection rate for multiplex selection in vivo
11,12
.  
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Intrigued by this concept, I  adapted a recently developed approach to transfect the germ cells in 
the testis
21
 to render it compatible with linear DNA libraries expressing small hairpin RNA 
(shRNA) (Figures 2.1a, 2.1b). The technique uses a buffered salt solution to generate an osmotic 
gradient which drives water and the dissolved DNA into the germ cells of the testis at a 
reasonably high rate. A similar approach using electroporation has been shown to work for a 
single shRNA in spermatogenesis
22
.  
 
I demonstrate the feasibility of using this low cost transfection method in mouse testes to screen 
multiple genes simultaneously for functional importance in spermatogenesis. By carefully 
designing the pilot study, I was also able to benchmark this system to prove the importance of 
large numbers of biological replicates and quantify the limits of this system. I also applied this 
method to establish the functional importance of twenty six uncharacterized genes that I 
previously predicted to be important for infertility via machine learning
23
.  
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Figure 2.1a: Overview of Experimental approach (Transfection and Selection) 
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Figure 2.1b: Overview of Experimental approach (Sequencing) 
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Chapter 2 - Results 
Pilot shRNA screen 
As a proof-of-concept for this technique, we designed a pilot shRNA pool targeting 4 classes of 
genes: i) sixteen genes that have been shown to cause assorted sperm development problems 
when knocked out (BAX, CSF, KIT, PIN1, CPEB1, GNPAT, MLH3, SPO11, CIB1, MAP7, 
PYGO2, TBPL1, SH2B1, TSN, SIRT1 & VDAC3); ii) five genes that have been characterized in 
knockout mice but have not been linked to spermatogenesis defects (MMP3, SYT4, TFF3, 
TNFSF4, TYRP1); iii) three genes that have no knockout mice made and are not expressed in 
mouse testis (APOC4, LCE1I, SCRG1); and iv) one gene that causes spermatogenesis failure 
when overexpressed but not reported to affect spermatogenesis when knocked out (VAMP7) 
(Table 2.1a). Our pool contained one hundred and nineteen unique RNAi with a mode of five 
RNAi per targeted gene. 
 
Instead of miRNA, I used small hairpin RNA (shRNA) expressing DNA sequences to induce 
knockdown of genes. By integrating the expression cassette into the genome, I got stable 
expression of the RNAi construct in transfected cells. I experimented with two different 
transfection methods, Tris-HCl with naked DNA and lentiviral infection. A single injection of a 
high titer (10
9
 Tu/ml) lentivirus produced a testis with a higher infection rate than an injection of 
Tris-HCl with 15µg of DNA. However, the single injection of lentivirus produced an infection 
rate was lower than five injections of the Tris-HCl DNA (Table 2.S1). Due to the lower infection 
rate, I observed low reproducibility and more dropout of shRNA samples in the single DNA and 
viral injection testes samples compared to the five DNA injection testes (Data not shown). Since 
the cost of performing five DNA injections is significantly lower than even one high titer 
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lentivirus injection (about $50 versus $250), I decided to proceed with that method rather than 
attempt multiple lentiviral injections.  
 
shRNA effect p.value 
 
shRNA effect p.value 
 
shRNA effect p.value 
BAX.1 1.491617 0.000233 
 
MTAP7.3 0.542848 0.477663 
 
MMP3.3 0.686643 0.013764 
BAX.2 0.644068 0.013938 
 
MTAP7.4 0.670612 0.352283 
 
MMP3.4 0.451533 0.583173 
BAX.3 0.685645 0.168694 
 
MTAP7.5 -1.24653 5.12E-07 
 
SCRG1.1 0.544988 0.091899 
BAX.4 -0.31448 8.51E-06 
 
PYGO2.1 0.524609 0.208095 
 
SCRG1.2 1.06915 0.002892 
BAX.5 0.505972 0.093362 
 
PYGO2.2 0.051773 0.004198 
 
SCRG1.3 0.419343 0.995189 
CSF1.1 0.407182 0.72313 
 
PYGO2.3 -0.31263 2.29E-05 
 
SCRG1.4 0.553699 0.106069 
CSF1.2 -0.07141 0.001372 
 
PYGO2.4 0.111512 0.024783 
 
SYT4.1 0.45195 0.276389 
CSF1.3 0.89958 0.001235 
 
PYGO2.5 0.512162 0.151658 
 
SYT4.2 0.531955 0.04626 
CSF1.4 -0.34712 2.03E-05 
 
TBPL1.1 0.777065 0.014903 
 
SYT4.3 0.273697 0.726521 
CSF1.5 -0.14532 0.000956 
 
TBPL1.2 -0.51976 2.61E-06 
 
SYT4.4 0.05074 0.00406 
KIT.1 -0.79134 8.43E-07 
 
TBPL1.3 0.195934 0.04384 
 
SYT4.5 0.683667 0.032538 
KIT.2 0.528862 0.163166 
 
TBPL1.4 0.231028 0.060116 
 
TFF3.1 0.82922 0.162711 
KIT.3 0.020387 0.00143 
 
TBPL1.5 0.518287 0.446464 
 
TFF3.2 0.343532 0.844622 
KIT.4 0.602483 0.124486 
 
SH2B1.1 0.765325 0.002878 
 
TFF3.3 0.829876 0.012541 
PIN1.1 0.953665 0.005774 
 
SH2B1.2 0.933765 0.000451 
 
TFF3.4 0.116672 0.017221 
PIN1.2 0.018609 0.000796 
 
SH2B1.3 0.769163 0.002822 
 
TFF3.5 0.176176 0.093067 
PIN1.3 0.998499 0.000163 
 
SH2B1.4 1.154908 0.000446 
 
TNFSF4.1 -0.53715 1.87E-06 
PIN1.4 0.477457 0.838727 
 
SH2B1.5 -0.17093 6.43E-05 
 
TNFSF4.2 0.580482 0.026477 
PIN1.5 -0.28984 1.27E-05 
 
TSN.1 -0.25881 9.15E-05 
 
TNFSF4.3 0.450666 0.679552 
CPEB1.1 0.704452 0.014293 
 
TSN.2 0.496608 0.052717 
 
TNFSF4.4 -0.04875 0.00037 
CPEB1.2 0.129264 0.005881 
 
TSN.3 0.021181 0.001147 
 
TNFSF4.5 0.353803 0.692855 
CPEB1.3 -0.12752 0.000212 
 
TSN.4 0.411955 0.834017 
 
TYRP1.1 0.061815 0.043682 
CPEB1.5 -0.38412 6.24E-06 
 
TSN.5 -0.07945 0.000632 
 
TYRP1.2 0.145296 0.009266 
GNPAT.1 -0.28982 1.97E-05 
 
SIRT1.1 0.25307 0.098167 
 
TYRP1.3 0.275121 0.923136 
GNPAT.2 -0.12214 6.43E-05 
 
SIRT1.2 -0.44504 7.50E-06 
 
VAMP7.1 -0.36238 9.46E-06 
GNPAT.3 -0.20153 0.0002 
 
SIRT1.3 -0.30681 9.52E-06 
 
VAMP7.2 0.270951 0.254401 
GNPAT.5 0.050146 0.001491 
 
SIRT1.4 -0.07802 0.000331 
 
VAMP7.3 0.820457 0.001899 
MLH3.1 0.910026 0.001184 
 
SIRT1.5 -0.06165 0.000355 
 
VAMP7.4 0.228109 0.090742 
MLH3.2 -0.27059 0.000129 
 
VDAC3.1 0.307419 0.182138 
 
VAMP7.5 -0.52979 5.93E-06 
MLH3.3 0.008727 0.003498 
 
VDAC3.2 0.005379 0.001009 
 
VAMP7.6 0.299056 0.657602 
MLH3.4 0.614311 0.058491 
 
VDAC3.3 -0.73389 2.43E-06 
 
VAMP7.7 0.407084 0.566728 
MLH3.5 -0.49274 6.06E-06 
 
VDAC3.4 0.821601 0.005827 
    
SPO11.1 0.857416 0.030513 
 
VDAC3.5 0.430334 0.977149 
    
SPO11.2 0.47177 0.734457 
 
APOC4.1 0.519536 0.597742 
    
SPO11.3 -0.16073 5.17E-05 
 
APOC4.3 0.447127 0.213038 
    
SPO11.4 -0.38517 1.57E-05 
 
APOC4.4 0.831132 0.134781 
    
SPO11.5 -0.29551 2.83E-05 
 
APOC4.5 0.330404 0.861175 
    
CIB1.1 -0.17637 3.64E-05 
 
APOC4.6 0.650361 0.283096 
    
CIB1.2 0.80193 0.005022 
 
LCE1I.1 0.476054 0.162711 
    
CIB1.3 0.010345 0.001795 
 
LCE1I.2 0.651527 0.040335 
    
CIB1.4 0.319618 0.912368 
 
LCE1I.4 0.845046 0.005963 
    
CIB1.5 0.750991 0.002993 
 
LCE1I.5 0.761141 0.019769 
    
MTAP7.1 0.663119 0.016325 
 
MMP3.1 -0.59078 2.08E-06 
    
MTAP7.2 1.050326 0.000131 
 
MMP3.2 0.180992 0.194799 
    
Table 2.1a: Pilot shRNA pool screen effect sizes and p values (testis) 
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A combined survival/differentiation selection pressure was applied on the germ cells in the testis 
by waiting for a sufficient length of time (20 days or slightly longer than half of a murine 
spermatogenesis cycle) after transfection before quantification. I assumed that any DNA injected 
into a mouse testis would not transfect the other testis because it would first have to pass through 
a large part of the rest of the body via the circulatory system. Indeed, the Pearson correlation of 
the shRNA pools between different testes in the same mouse was not significantly different than 
between testes from different mice. This allowed us to use the two testes in a mouse as different 
biological replicates or even to test different shRNA pools, halving the mouse requirements for 
our experiments.  
 
To analyze the data, I used a non-parametric Wilcoxon Rank Sum Test. I expected that many 
shRNAs would be non-functional, but some of the shRNAs against important spermatogenesis 
genes would be effective and knockdown expression, causing the cell to either arrest 
developmentally or undergo apoptosis. Those shRNAs would be depleted in the testis relative to 
non-functional shRNAs. Naively, you would compare the fold change of the shRNA across 
biological replicates and compare it to the overall population fold changes. However, that would 
rely on the ratio of effective shRNAs to the non-functional shRNAs to remain low. I instead 
spiked in a small number of negative control shRNAs into the pool to act as our miner’s canary; I 
compared the fold change of any shRNA against only the negative control shRNA fold changes. 
Due to the low transfection efficiency (1-3%) (Table S1), multiplicity of infection, a common 
issue in RNAi screens, was not a worry in the analysis. 
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Of the sixteen genes that have been reported to cause sperm development problems when 
knocked out in mice, twelve of them had at least two shRNAs be significantly depleted (P ≤ 
0.01) in the testis compared to the injected pool. This produces a 25% false negative rate (4/16). 
One of the eight negative control genes [groups (ii) and (iii)], TNFSF4 (moderately expressed in 
the testis), also passed our screen, producing a false positive rate of 12.5% (1/8). (Figure 2.2)  
 
Figure 2.2: Pilot shRNA pool screens results 
Each cell shows the log2 fold change of a shRNA against the target gene on the right from what 
was injected until after incubation in the mouse testis. Each row is arranged in ascending order 
based on the log2 fold change. If a cell is shaded, it means that it passes the significance 
threshold, which is annotated below the respective figure. Cells are shaded orange for 
significant depletion and white for significant enrichment. Predicted gene function on different 
stages of spermatogenesis is annotated to the left using a color bar. 
 
VAMP7, has been shown to cause spermatogenic failure when overexpressed in mice
24
, and the 
two studies examining the knockout mouse focused more on behavior and neurons than the 
reproductive system
25,26
. Because of these lines of evidence, I thought it was possible that 
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VAMP7 might also cause subfertility when knocked out in mice. VAMP7 did pass our 
knockdown screen, providing strong evidence for that hypothesis. 
Our criterion of requiring any given gene to have two different shRNAs to be significantly 
depleted might limit how low the false negative rate can go, since if a given gene has only one 
effective shRNA in the pool it can never pass. Indeed if we look at the false negatives in our 
pool, all of them (BAX, MTAP7, and SH2B1) simply had only one shRNA that was depleted 
(albeit very strongly). However, if we were to remove this requirement, our false positive rate 
would drastically increase to 50% (4/8). Since this is a method for large scale screening, missing 
some true positives is preferable to implicating excess false positives. Another way of resolving 
this issue may be to increase the average number of shRNAs per gene (5) that is used in the pool.  
 
One drawback of this approach is that both genes that are important for spermatogenesis and 
genes that are required for cell survival will be highlighted. By transfecting the same shRNA 
pool into an unrelated cell line and performing a survival screen on the cells, one should be able 
to highlight only genes needed for survival. A simple elimination filter on the original 
highlighted group of genes will then produce a list of genes that only affect spermatogenesis.  
 
I transfected three separate wells of Neuro-2a cells (N2a), prepared sequencing libraries, and 
analyzed the data through the same pipeline as the testis samples (Methods). The normalized 
read counts of the shRNA pool before and after the transfection and incubation was not well 
correlated with the testis read counts (Figure 2.3). Furthermore none of the shRNAs that were 
significantly depleted in the testes samples were also significantly depleted in the cell line 
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(Figure 2.2). I thus concluded that the genes with multiple shRNAs depleted in testes affect 
spermatogenesis and not survival. 
 
Figure 2.3: Clustering and correlations fold changes of the shRNAs across testes and cell 
lines 
 
Benchmarking the performance 
The first question with RNAi screening experimental designs is how many biological replicates 
to use. Increasing the number of biological replicates enables the discovery of genes with subtler 
effects, but there must be a point of diminishing returns for any given effect size, where more 
biological replicates do not significantly increase discovery power. I found that with more 
stringent significance thresholds and less biological replicates, the minimum detectable effect 
size decreased. For a lenient (P ≤ 0.1), standard (P ≤ 0.05), and stringent(P ≤ 0.01) p value 
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thresholds there was little improvement in detectable effect size beyond 3-4, 4-5, and 6-7 
biological replicates respectively (Figure 2.4). In order to reduce the chance of off-target effects, 
I required any given gene to have two different significantly depleted shRNAs before the gene 
was determined to have a spermatogenesis function. Thus, the P value for the lenient cutoff was 
really 0.01 (0.1
2
) and the stringent cutoff was 0.0001 (0.01
2
) (each shRNA works independently 
of each other in different cells, so the likelihood of two of them being depleted is the square of 
the cutoff). 
 
 
Figure 2.4: Screening method performance benchmarks 
Figure A shows the effect of biological replicates on minimum detectable shRNA fold change. 
The yellow line plots the median minimum log2 fold change that was observed by any shRNA that 
passed the p value threshold of p ≤ 0.1 in the pilot pool for varying amounts of biological 
replicates. In the lighter shaded area it shows 1 standard deviation from that observed minimum 
log2 fold change. In purple shows a similar plot for p ≤ 0.05 and in blue shows the plot for p ≤ 
0.01. Note that the blue starts at 3 biological replicates because there were no observations that 
passed that threshold before then. B shows the p value cutoffs for varying number of biological 
replicatesIn red there is the highest p-value (non-inclusive) that can be used to maintain the false 
positive rate, in blue is the lowest p-value (inclusive) that can be used to maintain the false 
negative rate. The shaded area behind each line represents the standard deviation for the cutoff 
values.  
 
Another reason to use more biological replicates is to minimize the false positives and false 
negatives. Among the significantly depleted shRNAs, I determined the largest p value of a called 
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gene and the lowest p value from an uncalled gene with varying numbers of biological replicates 
(Figure 2.4). The gap between the two values is an indicator of the likelihood of obtaining more 
false positives and negatives; a larger gap indicating a lower likelihood. Six replicates was the 
minimum number to avoid any overlap between the two p-value cutoffs within 1 standard 
deviation.  
 
Based on these analyses, I determined that 6-7 biological replicates were the optimal amount. It 
was possible to use fewer biological replicates, but less stringent criteria needed to be applied. 
Importantly, the fold change of each shRNA remained consistent across the biological replicates, 
but increasing the biological replicates allowed us to call smaller fold enrichment scores as 
significant. Using fewer biological replicates also sometimes slightly increased the number of 
false positives and/or negatives (depending on the combination of replicates used). 
 
Screening for uncharacterized predicted fertility genes 
Next I implemented this screening technique for the top candidate spermatogenesis genes that I 
had previously identified
23
 (Methods). In this new screen I used a pool comprising of one 
hundred and thirty shRNAs against twenty-six candidate genes and fifteen of the previously 
validated negative control shRNAs. Of the twenty-six candidate genes, there were four genes 
which are expressed early in spermatogenesis (ALPI, POLA1, RFC1, RRM1), fifteen genes 
which start expression in the middle of spermatogenesis (CRISP2, GSTM5, HRASLS5, 
KLHDC3, LDHAL6B, PGAM2, PHF7, PHKG2, RFC2, SFI1, SPATA4, TAF9, TCP1, TCP11, 
ZMYND10), and seven genes which are only expressed late in spermatogenesis 
(4933411K16Rik, ACTL7B, GSG1, MEA1, SPA17, SPZ1, UGT1A1) (Table 2.1b). I visualized 
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the functional relationships of these genes with other known spermatogenesis genes (Figure 
2.S2). 
shRNA effect p.value 
 
shRNA effect p.value 
 
shRNA effect p.value 
Actl7b.1 0.015889 0.000258 
 
Rfc4.5 -0.36645 1.15E-05 
 
Phkg2.3 -0.52569 1.03E-05 
Actl7b.2 -0.45539 1.09E-05 
 
Sfi1.1 0.410412 0.152605 
 
Phkg2.4 0.278501 0.019082 
Actl7b.3 -0.35963 1.15E-05 
 
Sfi1.2 -0.85623 1.03E-05 
 
Phkg2.5 0.50972 0.772978 
Actl7b.4 -0.1669 1.68E-05 
 
Sfi1.3 -0.60622 1.03E-05 
 
Rfc2.1 0.196714 0.014684 
Actl7b.5 -0.31619 1.15E-05 
 
Sfi1.4 -0.58489 1.09E-05 
 
Rfc2.2 0.643957 0.952076 
Alpi.1 1.099163 0.057542 
 
Sfi1.5 0.212698 0.051504 
 
Rfc2.3 0.111148 0.001851 
Alpi.2 -0.46416 1.09E-05 
 
Spa17.1 -0.41977 1.78E-05 
 
Rfc2.4 -0.0854 8.91E-05 
Alpi.3 0.197698 0.002453 
 
Spa17.2 0.328957 0.079271 
 
Rfc2.5 0.585693 0.980821 
Alpi.4 0.193738 1.42E-02 
 
Spa17.3 0.136686 0.009098 
 
Rrm1.1 -0.12047 5.66E-05 
Alpi.5 -0.4806 1.09E-05 
 
Spa17.4 -0.37063 1.21E-05 
 
Rrm1.2 0.464185 0.206909 
Crisp2.1 -0.16214 3.94E-05 
 
Spa17.5 -0.6222 1.03E-05 
 
Rrm1.3 0.337198 0.064156 
Crisp2.2 -0.82978 1.03E-05 
 
Spata4.1 0.722841 0.441724 
 
Rrm1.4 0.482805 0.301263 
Crisp2.3 0.342999 0.118144 
 
Spata4.2 0.022258 0.000297 
 
Rrm1.5 -0.37315 1.21E-05 
Gsg1.1 -0.14535 5.10E-05 
 
Spata4.3 -0.39323 1.15E-05 
 
Spz1.1 -0.10458 9.84E-05 
Gsg1.2 -0.1723 6.59E-05 
 
Spata4.4 -0.46324 1.09E-05 
 
Spz1.2 0.229612 0.008783 
Gsg1.3 0.569979 0.463421 
 
Tcp1.1 0.265696 0.016216 
 
Spz1.3 0.883214 0.243635 
Gsg1.4 0.419867 0.112592 
 
Tcp1.2 -0.29274 1.35E-05 
 
Spz1.4 -0.35202 1.09E-05 
Gsg1.5 0.272286 0.039837 
 
Tcp1.3 -0.36721 1.21E-05 
 
Spz1.5 0.040797 0.000764 
Gstm5.1 0.172666 3.23E-03 
 
Tcp1.4 -0.16012 1.59E-05 
 
Taf9.1 0.073342 0.000428 
Gstm5.2 0.007751 0.000214 
 
Tcp1.5 -0.03193 0.000109 
 
Taf9.2 0.925805 0.020348 
Gstm5.3 -0.10902 5.95E-05 
 
Tcp11.1 -0.23818 4.85E-05 
 
Taf9.3 0.054157 0.002265 
Gstm5.4 0.035054 0.000224 
 
Tcp11.2 0.159007 0.004732 
 
Taf9.4 0.12965 0.107247 
Gstm5.5 0.157049 2.01E-03 
 
Tcp11.3 -0.81735 1.03E-05 
 
Taf9.5 -0.32276 1.35E-05 
Hrasls5.1 0.047816 4.48E-04 
 
Tcp11.4 0.168265 0.007352 
 
Ugt1a1.1 -0.29293 1.28E-05 
Hrasls5.2 -0.07538 6.59E-05 
 
Tcp11.5 0.93258 0.092411 
 
Ugt1a1.2 -0.64813 1.03E-05 
Hrasls5.3 0.642644 0.932945 
 
4933411K16Rik.1 -0.03061 0.000177 
 
Ugt1a1.3 0.959077 0.079271 
Hrasls5.4 0.593571 0.763794 
 
4933411K16Rik.2 0.081464 0.000833 
 
Ugt1a1.4 0.650001 0.99041 
Hrasls5.5 0.110306 0.002265 
 
4933411K16Rik.3 -0.55283 1.09E-05 
 
Ugt1a1.5 -0.39812 1.09E-05 
Mea1.1 0.307722 0.052962 
 
4933411K16Rik.4 0.565777 0.84749 
 
Zmynd10.1 0.442424 0.224737 
Mea1.2 0.885945 0.290161 
 
4933411K16Rik.5 0.567327 0.324306 
 
Zmynd10.2 -0.79687 0.000469 
Mea1.3 0.061647 0.001927 
 
Klhdc3.1 0.282169 0.023835 
 
Zmynd10.3 -1.03077 6.26E-05 
Mea1.4 -0.62207 1.03E-05 
 
Klhdc3.2 0.134523 0.005099 
 
Zmynd10.4 -0.35061 1.21E-05 
Mea1.5 0.83258 0.295677 
 
Klhdc3.3 0.1164 0.002453 
 
Apoc4.1 0.784977 0.116731 
Pgam2.1 -0.08581 0.000204 
 
Klhdc3.4 0.161291 0.004389 
 
Apoc4.2 0.509159 0.643522 
Pgam2.2 0.45828 3.74E-01 
 
Klhdc3.5 0.096172 0.004913 
 
Apoc4.3 1.430087 0.005195 
Pgam2.3 0.505186 3.61E-01 
 
Klhdc3.6 0.817036 0.373742 
 
Apoc4.4 0.677533 0.364126 
Pgam2.4 0.465959 4.63E-01 
 
Ldhal6b.1 -0.37889 1.15E-05 
 
Apoc4.5 0.177995 0.032876 
Pgam2.5 -0.80073 1.03E-05 
 
Ldhal6b.2 -0.56104 1.03E-05 
 
Syt4.1 0.43407 0.321357 
Pgam2.6 -0.05413 0.000109 
 
Ldhal6b.3 0.368932 0.238809 
 
Syt4.2 0.713099 0.266192 
Pgam2.7 1.217661 0.010103 
 
Ldhal6b.4 0.448284 0.21569 
 
Syt4.3 0.106947 0.014929 
Pola1.1 -0.09564 4.61E-05 
 
Ldhal6b.5 0.487051 0.301263 
 
Tff3.1 1.22015 0.015432 
Pola1.2 -0.19154 4.61E-05 
 
Ldhal6b.6 1.212021 0.01518 
 
Tff3.2 0.765601 0.678362 
Pola1.3 0.333183 0.046006 
 
Phf7.1 -0.0998 2.59E-05 
 
Tff3.3 0.729007 0.28201 
Pola1.4 0.416431 0.198391 
 
Phf7.2 -0.13254 1.88E-05 
 
Tff3.4 0.200792 0.045352 
Pola1.5 0.109785 0.001507 
 
Phf7.3 0.026095 0.00067 
 
Tff3.5 0.29828 0.213464 
Rfc4.1 0.290864 0.012413 
 
Phf7.4 -0.06238 9.36E-05 
 
SHC202 0.621188 0.805361 
Rfc4.2 0.308573 0.033374 
 
Phf7.5 0.167073 0.001705 
 
SHC216 0.59584 0.438158 
Rfc4.3 0.300248 0.038691 
 
Phkg2.1 -0.18144 2.88E-05 
    
Rfc4.4 -0.26783 1.28E-05 
 
Phkg2.2 -0.8624 1.03E-05 
    
Table 2.1b: Predicted genes’ shRNA pool screen effect sizes and p values (testis) 
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Similar to the previous pool, we also transfected this pool into N2a cells to eliminate the 
possibility that these genes are required for general cell survival. Only two genes (MEA1 and 
TAF9) had at least two shRNAs that were significantly depleted (P ≤ 0.01) (Figure 2.5). Overall, 
the normalized read counts of the shRNA pool in N2a cells were not well correlated with the 
testis read counts (Figure 2.6).  Given this, we concluded that most of the genes with multiple 
shRNAs depleted in testes (24/26) affect spermatogenesis and not survival. 
 
 
Figure 2.5: Predicted genes’ shRNA pool screens results  
See Figure 2.3 for plot explanation 
 
Given that I tested the top candidates in a list of close to a thousand, it is not too surprising that 
most of the candidate genes passed the screen. Furthermore, most of the genes are predicted to 
have functions that are closely related to meiosis. Seven genes are thought to be involved in cell 
cycle (ACTL7B, KLHDC3, POLA1, RFC2, RFC4, RRM1, SFI1), seven in metabolism (ALPI, 
GSTM5, HRASLS5, LDHAL6B, PGAM2, PHKG2, UGT1A1), three transcription factors 
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(OHF7, SPZ1, ZMYND10), two protein folding (TCP1, TCP11), one cell binding in sperm 
(SPA17), and one involved in capacitation of the membrane (CRISP2).  
 
Figure 2.6: Clustering and correlations fold changes of the shRNAs across testes and cell 
lines 
 
I performed a functional pathway analysis of these genes and found four functional networks. All 
twenty five tested genes were linked to the twenty associated genes in the co-expressed network, 
which tests for similar expression levels across different conditions in various published Gene 
Expression Omnibus (GEO) datasets. In the predicted network, which uses protein interactions 
and orthologous functional relationships from other organisms I found three isolated networks. 
The largest network links sixteen of the tested genes with seventeen other genes, fourteen of 
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which are annotated with GO terms related to sperm function. The next largest network groups 
six of the genes together. Four of the genes were not functionally associated with any other 
sperm function gene. The co-localized network identifies genes expressed in the same tissue. 
This produced a large network linking thirteen of the tested genes with fifteen associated genes 
and two smaller networks linking three and two tested genes respectively. Lastly I had the shared 
protein domain network which links genes if their product has a common protein domain. This 
was the sparsest network with three tested genes linked to each other and two tested genes linked 
to one spermatogenesis associated gene each. (Figure S2). 
 
 
Chapter 2 - Discussion 
The performance of our direct in vivo screen is comparable to other benchmarked RNAi screens 
performed in other model systems. Our false negative rate of 25% is up to the standards of 
various studies benchmarking RNAi screens for different pathways in drosophila 
melanogaster
27–30
 where it was reported to be between 13% and 50%. Our false positive rate of 
12.5% also compares favorably to the same study
30
 which found their false positive rates to be 
between 7% and 18%.  
 
Over half (65/121) the shRNAs in the pilot pool and about a third of the shRNAs (48/145) in the 
predicted gene pool were reported by Sigma-Aldrich to be validated in various cell lines 
(Supplemental Table 2.1 & 2.2). There was at least one validated shRNA for 72% (18/25) of 
the pilot pool genes and 45% (13/29) of the predicted pool genes. While not all the validated 
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shRNAs were consistently significantly depleted in the two studies, many of them were, giving 
us confidence that the signal I observed was not caused by off-target effects. 
 
Going forward, I think that it will be important to create a method to verify spermatogenesis 
genes without having to make knockout mice. I am working on adapting the transfection 
protocol to accomplish this. I am also interested in looking at the functions of the twenty one 
genes identified by this screen, especially the three genes of unknown molecular function 
(4933411K16Rik, GSG1, and SPATA4). These genes could work in novel pathways, providing 
new insights about spermatogenesis.  
 
I was extremely conservative with the multiplexity of the pool in this study. In order to produce 
reproducible signals I ensured that the number of cells was orders of magnitude larger than the 
number of shRNAs. In this manner I could be confident that no shRNA would be 
underrepresented in the final pool due to transfection efficiency. Even with the relatively low 
transfection rate, I was able to get consistent signals using pools consisting of up to 
approximately 150 shRNAs. It required about 2% of the total genomic DNA extracted from a 
testis to make a library and MiSeq to sequence the libraries. It is conceivable to scale up the 
number of shRNAs in the pool up to ten times without changing any other parameters other than 
using ten times more of the genomic DNA to make sequencing libraries and changing to the 
HiSeq system for sequencing which will produce ten times more sequencing reads in one 
sequencing lane. Taking advantage of this increase in throughput, one could both increase the 
number of genes screened and increase the number of shRNAs used per gene to potentially 
reduce the false negative rate. 
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Figure 2.7: Technical and biological noise in the shRNA pools 
This visualizes standard error as a proportion of the median normalized count values of each 
shRNA within each sample in box plot form. In blue are the errors for libraries prepared from 
the PCR product injected into the testes. Due to the large numbers of shRNA, this is a good 
quantification of the technical noise. In red are the errors for the median counts across all testes 
samples, a measure for the biological noise. In purple are the errors within a testis sample, 
measuring the sum of the biological and technical noise. 
 
To make this protocol accessible I used a total of 31 cycles of PCR to prepare the sequencing 
libraries. This produced nearly two orders of magnitude more material than was required for 
sequencing on one Illumina lane, raising concerns about overamplification. However I found that 
the technical noise inherent in each sample was within the same scale as the noise between 
biological samples (Figure 2.7), meaning it does not cause too much problem in the downstream 
analyses. If technical noise is a concern, it is possible to reduce the number of PCR cycles in the 
first step of library preparation and still have sufficient amounts of DNA for sequencing. 
However a more sensitive method of DNA quantification such as a Bioanalyzer chip will be 
required in that case. 
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I made an attempt to decipher the functional effects of the genes via this same technique by using 
cell stage and functional separation (FACS and sperm motility assays respectively). 
Unfortunately because the number of cells I could retrieve in this manner was limited, I was 
unable to prepare sequencing libraries from the subpopulations. If I could transfect a majority 
(60-80%) of the cells (perhaps by multiple lentivirus injections), or if it was possible to sort and 
retrieve large numbers of cells (10s of millions), direct functional assays using an RNAi pool 
may be possible. More technically challenging protocols such as efferent duct injection or in-
vitro organogenesis may be required to enable such future experiments. 
 
For other groups intending to use this technique, I would like to provide some words of caution. 
Firstly, the fold changes are a relative measure of the strength of the RNAi relative to each other 
RNAi in the pool. Furthermore, fold change convolutes gene functional effect and RNAi 
knockdown efficiency. As such, I would advise against using the extent of the fold change of a 
RNAi to rank gene functional effects. Finally, the analysis I used requires some known negative 
controls spiked into the pool. I recommend using the ones against the 7 negative control genes 
that did not produce false positives in the pilot pool. Our experimental protocol (Supplementary 
Protocol 2.1, 2.2) and analysis pipeline are provided to make it easy for any other interested 
groups to try this technique on shRNA pools of their own design against genes of their interest. 
Based on our benchmarks, I would recommend that they use at least 6-7 biological replicates for 
good confidence in their results. 
 
Via the traditional method of making knockout mice to validate gene function, it would have 
been unreasonably time consuming and expensive to test all twenty-six candidate genes, despite 
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them being the very top candidates in a list of near a thousand genes. Using our screening 
technique I was able to quickly produce experimental evidence for their functional effect. I 
expect this technique to be useful to help narrow down the large lists of genes that will be 
generated from large scale exome studies of infertility that are currently underway. 
 
 
Chapter 2 - Methods 
Gene Selection 
For the initial pool, I used data from the Mouse Genome Database
31
 from Jackson Labs (MGI) to 
create a list of genes that affect the male reproductive system when knocked out. I then used a 
list of genes that have been knocked out and not reported to cause any male reproductive defects 
to use as negative controls.  
For the predicted spermatogenesis gene pool, picked the top 30 candidates from each of the 
mouse predicted infertility gene models
23
 and filtered it to keep only the genes that were not 
reported in MGI to have any knockout mice line made. I then used shRNAs against three of the 
known negative genes from the pilot pools together with two scrambled non-mammalian 
sequences to use as negative controls. 
 
shRNA Pool Preparation 
I used RNAi from the MISSION® TRC-Mm 1.5 and 2.0 (Mouse) obtained from Sigma-Aldrich 
(Supplemental Table 2.1 & 2.2) ordered as shRNA plasmids. The shRNA expression cassette 
from the plasmids was amplified from the plasmid pool by PCR and purified using AMPure XP 
beads (Supplementary Protocol 2.2). These purified amplicons were pooled and then used for 
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injection into mouse testis and transfection into cell lines. An aliquot of this mixture was 
sequenced on MiSeq to determine initial shRNA pool composition. 
 
Mouse Testis Transfection 
I performed the experiments using C57BL/6 mice generated in house between 28-32 days of age. 
All mice were maintained under pathogen-free conditions and all animal experiments were 
approved by Washington University’s Animal Studies Committee. Each mouse received bilateral 
intra-testicular DNA injections five times, spaced 3-4 days apart (Supplementary Protocol 2.1). 
Following the injections, the mice were allowed to recover until 20 days after the third injection, 
when testes were dissected. Genomic DNA from the whole testis was extracted using Qiagen 
DNeasy Blood and Tissue kit. 
 
Cell Line Transfection 
N2a cells were maintained in Minimum Essential Media (MEM) supplemented with 10% Fetal 
Bovine Serum (FBS) until they reached 60% confluency in 6 well cell culture plates. Each well 
of cells was transfected with 2.5µg shRNA pool DNA using Lipofectamine® 3000 (Life 
Technologies) following manufacturer’s instructions. The cells were then incubated at 37°C for 2 
days, with daily media replacement, before the genomic DNA was extracted using the Qiagen 
DNeasy Blood and Tissue Kit. 
 
Illumina Sequencing Library Preparation 
I used a custom protocol to amplify the shRNA sequences in the genomic DNA samples 
(Supplementary Protocol 2.2). This protocol used 2 rounds of PCR amplification to prepare the 
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sequencing library instead of ligation followed by PCR amplification. I started with 2µg of 
genomic DNA to survey the genomes of enough cells in order to reduce the likelihood of dropout 
or PCR jackpotting; common artifacts when testing low numbers of cells. 
 
Each biological sample had between three to five separate sequencing libraries prepared with 
different indices using different aliquots of genomic DNA to quantify technical noise. 
Sequencing libraries were then pooled and run in a lane of Illumina MiSeq 2x150bp to obtain an 
average of at least 3,000 reads per unique shRNA in the library.  
 
Statistical Analysis 
Mapping of reads to shRNAs was done by aligning each read to the unique half of the hairpin 
sequence with no mismatches. A table of read counts for each shRNA was generated to 
determine significant enrichment/depletion. There was no significant difference in the counts 
between paired-end reads when they were mapped separately.   I minimized technical noise by 
using the median value of technical replicates as the true count for each shRNA. 
 
To determine significant depletion/enrichment of shRNAs, I used a custom R script. I started by 
normalizing the shRNA count data to number of reads per shRNA per million reads in the 
sequencing library. I then calculated the log 2 fold enrichment of each shRNA in the testis 
relative to the initial DNA pool. The fold changes of different experiments using the same 
shRNA pool design were always normalized to the sequencing counts of the actual injected 
material. These fold changes were then merged to produce more biological replicates for a given 
shRNA pool design. Finally, I performed a Wilcoxon Rank Sum Test for each shRNAs’ fold 
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enrichment across biological replicates against the fold enrichment of shRNAs against genes 
which are not known to affect spermatogenesis to calculate the likelihood that the shRNA was 
significantly depleted or enriched compared to the null. Any shRNA that had a p value smaller 
than the cutoff was determined to be significant. 
 
Network Analysis 
I used Cytoscape
32
 with the GeneMANIA plugin
33
 with the default settings to visualize the 
functional network of the tested predicted genes in the supplement. 
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Supplementary Protocol 2.1: Mouse Testis DNA transfection 
Materials Needed: 
 1M Tris-Hcl pH7.0 
 Pure, DNase and RNase free water 
 DNA to be injected 
 Anasthesia*  
 29 gauge Insulin Needle (Terumo: SS10M2913) 
 701N Syringe, Cemented Needle, 26s Gauge  (Hamilton: 80300) 
 70% Ethanol (denatured is fine) 
 100% pure Ethanol 
 Kimwipes 
Step 1: Prepare the DNA mixture 
If using linear DNA 
Dilute the DNA in Tris-Hcl and water to get 15µg of DNA in 20µl of 150mM Tris-HCL pH 7.0 
If using circular DNA 
Dilute the DNA in Tris-Hcl and water to get 15µg of DNA in 20µl of 125mM Tris-HCL pH 7.0 
 
Step 2: Anesthetize the mouse 
I used a mixture of (final concentrations) Ketamine (10mg/ml), Xylazine (1mg/ml), and 
Glycopyrrolate (2µg/ml) diluted in sterile PBS. This was injected intraperitoneally using a 29 
gauge needle, with 10µl of anesthesia used per 1g of mouse body weight. 
Alternative general anesthesia methods such as isoflurane can also be used 
Step 3: Injection of material 
First, wipe down the inferior torso (where the testis are) with 70% ethanol and a kimwipe. (This 
lattens the fur and prevents it from interfering with the injection. 
Nest, feel for one of the mouse testis and get a good grip on it between your fingers. 
Using the 701N syringe, pipette 10µl of the DNA mixture form step 1 and inject it slowly 
through the skin into the anterior end of the testis. (This should take between 30s to 60s to finish 
injecting. I find that slower rates of injection lead to better transfection rates) Repeat this with the 
other 10µl using the same syringe into the posterior end of the testis. 
You can repeat the same procedure for the other testis. 
Following Injection, tap the testes gently about ten times with your finger to ensure that the DNA 
mixture is spread throughout the testis. 
At the end, clean the syringe by pulling up 100% ethanol through it three times and wiping down 
the needle using a kimwipe and 100% ethanol. 
To prevent contamination, I like to use different 701N syringes for different DNA mixtures. 
However, the same syringe can be used on multiple different testes if you are using an identical 
DNA mixture for all of them. 
I spaced the injections 3-4 days apart (twice a week) to allow the testis to heal from the prior 
injection. 
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Supplementary Protocol 2.2: shRNA pool DNA Preparation (For Injection) 
Materials Needed: 
 Q5 Hot Start DNA polymerase*  [NEB: M0493L] 
 5M Betaine [Sigma-Aldrich: B0300-1VL/ B0300-5VL] 
 10mM dNTPs [Promega: U1511/U1515] 
 shRNA pool [Sigma-Aldrich: Mission® shRNA Library] 
 PCR Primers: (5’ to 3’)  
pLKO U6 shRNA F GAGGGCCTATTTCCCATGATTCC           
pLKO U6 shRNA R GTGGATGAATACTGCCATTTGTCTC 
 Ampure XP beads [Beckman Coulter: A63880/A63881/A63882] 
 70% Ethanol 
 Magnetic separation rack for 1.5ml microcentrifuge tubes 
*(I have found Q5 to be more sensitive and specific than Taq or Phusion, and this improvement 
is necessary for amplifying from low amounts of sample.) 
 
 
Step 1: Mix shRNA pool 
I ordered shRNAs in plasmid form in the 96-well plate format. Taking 5µl of the plasmid each 
shRNA I wanted in the pool I made a pool of over a hundred shRNAs at a final concentration of 
around 20ng/µl. This was mixed via a 10 second vortex and spun down briefly to collect all the 
liquid at the bottom of the tube. 
 
 
Step 2: PCR Amplification of shRNA pool 
Each PCR reaction produces ~ 3-4µg of DNA, meaning around 20 reactions are needed for 
enough material for 1 testis (15µg/injection X 5 injections = 75µg).  
 
Per reaction, mix: 
10μM F and R Primers 0.4μM 2μl 
5X Q5 Buffer 1X 10μl 
10mM dNTPs 0.2mM 1µl 
Q5 Hotstart Polymerase 4 Units 2µl 
5M Betaine 1.5M 15µl 
DNA sample ~20ng 1µl 
Distilled H2O   19μl 
  50µl 
 
       PCR Conditions 
98°C for 3 minutes 
98°C for 30 seconds 
60°C for 30 seconds   35 Cycles 
72°C for 30 seconds 
72°C for 10 minutes 
4°C hold 
Expected product size is 343bp 
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Step 3: Clean-up of PCR products 
(Adapted from AMpure XP manufacturer’s protocol) 
1. Pool up to 10 reactions in a 1.5ml microcentrifuge tube. 
2. Add 1.8X volume of AMpureXP beads to the mixture (i.e. 900µl beads for a 500µl reaction mix) 
and incubate for 5 minutes at room temperature 
3. Place tubes in the magnetic separation rack for at least 1 minute. 
4. Without disturbing the beads on the side of the tube, pipette out the liquid leaving up to 20µl 
behind. 
5. While still on the rack, add 1ml of 70% ethanol to each tube to wash the beads. 
6. Incubate for 1 minute at room temperature. 
7. Pipette out all the liquid from each tube. 
8. Repeat Steps 5 to 7. 
9. Air dry the beads for 2 minutes at room temperature 
10. Remove tubes from rack and add 200µl of water/elution buffer to the beads, pipetting up and 
down to ensure all the beads are suspended. Sequentially take the same 200µl bead/water 
mixture and pipette into the other tubes, until there are 6 tubes worth of beads suspended in 
the water. 
11. Incubate at room temperature for a minimum of 5 minutes. 
12. Place tubes in magnetic separation rack and let it sit for 5 minutes. 
13. Without disturbing the beads on the side of the tube, pipette out the 200µl of liquid and put 
into a new tube. 
14. Quantify the concentration of DNA using a spectrophotometer. 
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Supplementary Protocol 2.2: shRNA pool Sequencing Library Preparation 
Materials Needed: 
 Q5 Hot Start DNA polymerase*  [NEB: M0493L] 
 5M Betaine [Sigma-Aldrich: B0300-1VL/ B0300-5VL] 
 10mM dNTPs [Promega: U1511/U1515] 
 DNA (input/genomic) 
 PCR Primers: (5’ to 3’)  
(Step 1 PCR primers) 
pLKO F CTCTTTCCCTACACGACGCTCTTCCGATCT  NNNN   CTTTATATATCTTGTGGAAAGGACGA 
pLKO R 
CTGGAGTTCAGACGTGTGCTCTTCCGATCT  NNNNNN     
TGGATGAATACTGCCATTTGTCTC 
Note: NNNN stands for four and NNNNNN stands for six random nucleotides. These are 
a mixture of 25% of each base and are required to avoid QC errors for Illumina 
sequencing since the library has a low complexity at the non-shRNA regions. 
 
(Step 2 PCR primers) 
PE PCR 
F 
AATGATACGGCGACCACCGAGATCTAC   
ACTCTTTCCCTACACGACGCTCTTCCGATCT 
PE PCR 
R 
CAAGCAGAAGACGGCATACGAGAT  XXXXXXXX  
GTGACTGGAGTTCAGACGTGTGCTCTTCCG 
Note: XXXXXXXX stands for the reverse complement of the index sequence used for 
multiplexing. This can be between 6-8 base pairs in length. Different R primers can be 
ordered and used with the F primer. If double indexing, add the reverse complement of 
the second index to the space in the F primer. 
 (Optional) Qiagen Minelute Kit [Qiagen: 28004] 
 Ampure XP beads [Beckman Coulter: A63880/A63881/A63882] 
 70% Ethanol 
 96-well magnetic separation plate 
*(I have found Q5 to be more sensitive and specific than Taq or Phusion, and this improvement 
is necessary for amplifying from low amounts of sample.) 
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Step 1: PCR amplification of shRNA sequences from sample 
Per reaction, mix: 
10μM pLKO F and R 
primers 
0.4μM 1μl 
5X Q5 Buffer 1X 5μl 
10mM dNTPs 0.2mM 0.5µl 
Q5 Hotstart Polymerase 2 Units 1µl 
5M Betaine 1.5M 7.5µl 
Genomic DNA sample ~2µg X µl 
Distilled H2O   
10-X 
µl 
  25µl 
 
 
       PCR Conditions 
98°C for 3 minutes 
98°C for 30 seconds 
60°C for 30 seconds   25 Cycles 
72°C for 30 seconds 
72°C for 10 minutes 
4°C hold 
*Note: If amplifying from input DNA pool, use ~100ng of sample. 
Expected product size is 196bp 
 
(Optional) Step 2: Purification of DNA sample 
This step removes excess primers which can inhibit the PCR reaction in step 3 
Use the Qiagen Minelute kit with the manufacturer’s protocol to purify, eluting the sample in 
10µl of EB. 
Alternative: Use the AMpure XP beads to purify the sample similar to step 4, scaling the volume 
of beads added to the 25µl PCR reaction volume (45µl of beads) and eluting in 20µl of 
water/elution buffer. 
 
Step 3: Illumina Library Preparation using PCR 
Per reaction, mix: 
10μM PE PCR F and R 
primers 
0.4μM 2μl 
5X Q5 Buffer 1X 10μl 
10mM dNTPs 0.2mM 1µl 
Q5 Hotstart Polymerase 4 Units 2µl 
5M Betaine 1.5M 15µl 
Step 1 DNA sample 
200-
500ng 
X µl 
Distilled H2O   20-X µl 
  50µl 
 
 
       PCR Conditions 
98°C for 3 minutes 
98°C for 30 seconds 
60°C for 30 seconds    6 Cycles 
72°C for 30 seconds 
72°C for 10 minutes 
4°C hold 
*Note: If planning to run different samples in the same sequencing lane, ensure that the F and R 
primer combination of indices are different for each sample so that you can demultiplex during 
analysis. 
If skipping Step 2, X should be half of the volume of the step 1 reaction (12.5µl) 
Expected product size is 260bp 
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Step 4: Illumina Sequencing Library Cleanup 
(Adapted from AMpure XP manufacturer’s protocol) 
1. Add 1.8X volume of AMpureXP beads to each reaction (i.e. 90µl beads for a 50µl reaction) and 
incubate for 5 minutes at room temperature 
2. Place tubes in the magnetic separation rack for at least 1 minute. 
3. Without disturbing the beads on the side of the tube, pipette out the liquid leaving up to 20µl 
behind. 
4. While still on the rack, add 200µl of 70% ethanol to each tube to wash the beads. 
5. Incubate for 1 minute at room temperature. 
6. Pipette out all the liquid from each tube. 
7. Repeat Steps 4 to 6. 
8. Air dry the beads for 2 minutes at room temperature 
9. Remove tubes from rack and add 40µl of water/elution buffer to the beads, pipetting up and 
down to ensure all the beads are suspended.  
10. Incubate at room temperature for a minimum of 5 minutes. 
11. Place tubes in magnetic separation rack and let it sit for 5 minutes. 
12. Without disturbing the beads on the side of the tube, pipette out the 40µl of liquid and put into 
a new tube. 
13. Quantify the concentration of DNA using a spectrophotometer. 
*Note: Different samples can be pooled to produce a pool withan equal amount of DNA per 
sample and run on one Illumina HiSeq/MiSeq sequencing lane if they are uniquely indexed.
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Figure 2.S1: Standard curve for Actin and shRNA qPCR primers 
Slope for the actin curve (green)  is -3.797 with an R
2
 of 0.998, corresponding to 83.374% primer 
efficiency. 
Slope for the shRNA curve (red) is -3.691 with an R
2
 of 0.996, corresponding to 86.614% primer efficiency. 
 
Sample 
Mean 
shRNA qPCR 
cycle 
Standard 
Deviation 
shRNA qPCR cycle 
Mean 
Actin qPCR 
cycle 
Standard 
Deviation 
Actin qPCR cycle 
Transfection 
Rate 
lentivirus 1 shot 
rep1 
25.48693275 0.980911136 15.87373199 0.650952438 0.001229082 
lentivirus 1 shot 
rep2 
30.67140961 0.239385545 20.69246101 0.140888497 0.000953849 
      
DNA 1 shot rep1 29.62903252 0.755530495 16.19665559 0.961291686 0.0000870752 
DNA 1 shot rep2 34.09828949 0.743369937 22.191576 0.202929765 0.000250706 
      
DNA 5 shots rep1 26.41898537 0.645285487 20.50484753 0.522136739 0.015962821 
DNA 5 shots rep2 25.82338905 0.411470205 21.09821939 0.416632252 0.036393577 
DNA 5 shots rep3 26.44046402 0.415599784 19.91761208 0.464417369 0.010468114 
DNA 5 shots rep4 25.54398956 0.581989333 19.63961601 0.557033598 0.016071226 
Table 2.S1: Infection Rates for various injection conditions 
Each sample was prepared using at least 3 qPCR replicates for each target (Actin, shRNA). The formula to calculate the transfection 
rate was   
1
2𝑠ℎ𝑅𝑁𝐴 𝑐𝑦𝑐𝑙𝑒 𝑐𝑜𝑢𝑛𝑡− 𝐴𝑐𝑡𝑖𝑛 𝑐𝑦𝑐𝑙𝑒 𝑐𝑜𝑢𝑛𝑡
 ×  
𝐴𝑐𝑡𝑖𝑛 𝑃𝑟𝑖𝑚𝑒𝑟 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
𝑠ℎ𝑅𝑁𝐴 𝑃𝑟𝑖𝑚𝑒𝑟 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
 
Assuming each cell has 1 copy of actin (haploid germ cell), this should provide the transfection rate of the shRNA in the test. 
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Figure 2.S2: Functional networks for predicted genes 
The black diamond nodes are genes that I tested in the predicted shRNA pool while gray circle 
nodes are genes predicted to be functionally related. Red gene names mean that the shRNA are 
annotated with GO terms that are related to sperm function, while black gene names have no 
such annotation. The four figures with identical nodes but different color lines indicate which 
GeneMANIA mouse network links the genes. 
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TRC.Id Clone.Name Region Gene RefSeq.Id Validated Cell.line Validate.Knockdown Target.Seq TRC.Version shRNA ID 
TRCN0000272981 NM_007527.3-409s21c1 CDS BAX NM_007527 Yes Hepa 1-6 0.75 GCAGCTGACATGTTTGCTGAT 2 BAX.1 
TRCN0000272982 NM_007527.3-323s21c1 CDS BAX NM_007527 Yes Hepa 1-6 0.88 GAGATGAACTGGACAGCAATA 2 BAX.2 
TRCN0000273037 NM_007527.3-631s21c1 CDS BAX NM_007527 Yes Hepa 1-6 0.86 TGGCAGACAGTGACCATCTTT 2 BAX.3 
TRCN0000273038 NM_007527.3-459s21c1 CDS BAX NM_007527 Yes Hepa 1-6 0.87 CCTCTTCTACTTTGCTAGCAA 2 BAX.4 
TRCN0000273039 NM_007527.3-488s21c1 CDS BAX NM_007527 Yes Hepa 1-6 0.9 TCAAGGCCCTGTGCACTAAAG 2 BAX.5 
TRCN0000305672 NM_007778.4-972s21c1 CDS CSF1 NM_007778 Yes Hepa 1-6 0.84 GCAACTGCCTGTACCCTAAAG 2 CSF1.1 
TRCN0000305733 NM_007778.4-634s21c1 CDS CSF1 NM_007778 Yes Hepa 1-6 0.89 TGATCCTGTTTGCTACCTAAA 2 CSF1.2 
TRCN0000305735 NM_007778.4-686s21c1 CDS CSF1 NM_007778 Yes Hepa 1-6 0.92 GATGAGACCATGCGCTTTAAA 2 CSF1.3 
TRCN0000324336 NM_007778.4-1939s21c1 CDS CSF1 NM_007778 Yes Hepa 1-6 0.79 CCTCCTGTTCTACAAGTGGAA 2 CSF1.4 
TRCN0000324337 NM_007778.4-2187s21c1 3UTR CSF1 NM_007778 Yes Hepa 1-6 0.88 GCCTACCAAGACTGGATGAAA 2 CSF1.5 
TRCN0000361294 NM_021099.3-3417s21c1 3UTR KIT NM_021099 
 
NA CCTTAATGATGGGAGATATAT 2 KIT.1 
TRCN0000361295 NM_021099.3-1198s21c1 CDS KIT NM_021099 
 
NA ACTTCGCCTGACCAGATTAAA 2 KIT.2 
TRCN0000361296 NM_021099.3-256s21c1 CDS KIT NM_021099 
 
NA ATGGACTTTCAAGACCTATTT 2 KIT.3 
TRCN0000368020 NM_021099.3-1318s21c1 CDS KIT NM_021099 
 
NA GACGTACGACAGGCTCATAAA 2 KIT.4 
TRCN0000321124 NM_023371.3-136s21c1 CDS PIN1 NM_023371 Yes NIH/3T3 0.87 TGTTGGAGGCAGCAGCAAGAA 2 PIN1.1 
TRCN0000321125 NM_023371.3-73s21c1 CDS PIN1 NM_023371 
 
NA GGTGTACTACTTCAATCACAT 2 PIN1.2 
TRCN0000321191 NM_023371.3-396s21c1 CDS PIN1 NM_023371 Yes NIH/3T3 0.89 GAGGTCAGATGCAGAAACCAT 2 PIN1.3 
TRCN0000321192 NM_023371.3-413s21c1 CDS PIN1 NM_023371 Yes NIH/3T3 0.89 CCATTTGAGGATGCGTCGTTT 2 PIN1.4 
TRCN0000321193 NM_023371.3-883s21c1 3UTR PIN1 NM_023371 Yes NIH/3T3 0.8 CCTACGCACCTTCCATTAAAT 2 PIN1.5 
           TRCN0000240542 NM_007755.4-972s21c1 CDS CPEB1 NM_007755 
 
NA GAGGCGTTCCTTGGGATATTA 2 CPEB1.1 
TRCN0000240543 NM_007755.4-1862s21c1 3UTR CPEB1 NM_007755 
 
NA GTCTTTGTTTCTGCACTAATT 2 CPEB1.2 
TRCN0000240544 NM_007755.4-1368s21c1 CDS CPEB1 NM_007755 Yes B16-F0 0.94 CCATCTTGAATGACCTATTTG 2 CPEB1.3 
TRCN0000240545 NM_007755.4-627s21c1 CDS CPEB1 NM_007755 
 
NA TGATTTCAAGCCTTCGCATTT 2 CPEB1.4 
TRCN0000240546 NM_007755.4-172s21c1 CDS CPEB1 NM_007755 Yes B16-F0 0.83 AGTCTGTACAACACCTATAAA 2 CPEB1.5 
TRCN0000277249 NM_010322.3-1022s21c1 CDS GNPAT NM_010322 Yes Hepa 1-6 0.97 GATACCTACTTTGTCCCAATT 2 GNPAT.1 
TRCN0000277250 NM_010322.3-1931s21c1 CDS GNPAT NM_010322 Yes Hepa 1-6 0.89 GTGGAATCATATCAGTTACTT 2 GNPAT.2 
TRCN0000277251 NM_010322.3-1226s21c1 CDS GNPAT NM_010322 Yes Hepa 1-6 0.91 CTCAATCGGAACACGTATAAC 2 GNPAT.3 
TRCN0000277252 NM_010322.3-437s21c1 CDS GNPAT NM_010322 
 
NA GAAGAGATCAACTATGTCATT 2 GNPAT.4 
TRCN0000277292 NM_010322.3-2704s21c1 3UTR GNPAT NM_010322 Yes Hepa 1-6 0.75 AGGACGTTCATGTCTAGATTA 2 GNPAT.5 
TRCN0000239426 NM_175337.1-291s21c1 CDS MLH3 NM_175337 
 
NA GAAGGTGGGAAACCGGTATTT 2 MLH3.1 
TRCN0000239427 NM_175337.1-518s21c1 CDS MLH3 NM_175337 Yes Hepa 1-6 0.77 GGACTACAGTAACGGTCTATA 2 MLH3.2 
TRCN0000239428 NM_175337.1-988s21c1 CDS MLH3 NM_175337 Yes Hepa 1-6 0.63 TCAGAACTCCACGGGATATAT 2 MLH3.3 
TRCN0000239429 NM_175337.1-1264s21c1 CDS MLH3 NM_175337 Yes Hepa 1-6 0.74 AGTTTCCGGGAAGCGTGTAAT 2 MLH3.4 
TRCN0000244279 NM_175337.1-4463s21c1 3UTR MLH3 NM_175337 Yes Hepa 1-6 0.66 CTCAAGCCTAAGGGTAGTTTA 2 MLH3.5 
TRCN0000271121 NM_012046.2-1224s21c1 CDS SPO11 NM_012046 
 
NA GGTTTGGAGGATGGATCTAAA 2 SPO11.1 
TRCN0000271122 NM_012046.2-719s21c1 CDS SPO11 NM_012046 Yes Hepa 1-6 0.8 GTCGAGAAGGATGCAACATTT 2 SPO11.2 
TRCN0000271124 NM_012046.2-443s21c1 CDS SPO11 NM_012046 
 
NA GCAACCAAGAGAGACATATAC 2 SPO11.3 
TRCN0000271125 NM_012046.2-900s21c1 CDS SPO11 NM_012046 
 
NA TCGAGATAATGTGCATCTATA 2 SPO11.4 
TRCN0000271173 NM_012046.2-1323s21c1 3UTR SPO11 NM_012046 
 
NA TCTTAGGTATGCAATGGTAAA 2 SPO11.5 
           TRCN0000328391 NM_011870.4-366s21c1 CDS CIB1 NM_011870 
 
NA CCAGACATCAAGTCACACTAT 2 CIB1.1 
TRCN0000328395 NM_011870.4-503s21c1 CDS CIB1 NM_011870 
 
NA GAAGCAGCTGATTGACAATAT 2 CIB1.2 
TRCN0000328454 NM_011870.4-602s21c1 CDS CIB1 NM_011870 
 
NA CTTTGCCAGCTCCTTTAAGAT 2 CIB1.3 
TRCN0000328455 NM_011870.4-642s21c1 3UTR CIB1 NM_011870 
 
NA AGTACCAACATCCTGTCCAAG 2 CIB1.4 
TRCN0000328456 NM_011870.4-548s21c1 CDS CIB1 NM_011870 
 
NA GGATGGGACCATCAATCTTTC 2 CIB1.5 
TRCN0000306401 NM_008635.2-959s21c1 CDS MTAP7 NM_008635 Yes Hepa 1-6 0.6 CATGGACTAGCGAGCCATAAA 2 MTAP7.1 
TRCN0000306402 NM_008635.2-1876s21c1 CDS MTAP7 NM_008635 Yes Hepa 1-6 0.73 GAGGACAGAGACCGCTGATAA 2 MTAP7.2 
TRCN0000306403 NM_008635.2-2720s21c1 3UTR MTAP7 NM_008635 
 
NA AGAGTGAGCGGAAGGTATTTA 2 MTAP7.3 
TRCN0000306462 NM_008635.2-2009s21c1 CDS MTAP7 NM_008635 Yes Hepa 1-6 0.67 AGCCCACATGGAGTCGCTTTA 2 MTAP7.4 
TRCN0000354145 NM_008635.2-696s21c1 CDS MTAP7 NM_008635 Yes Hepa 1-6 0.85 CCTCGTCTGCAACTTTGCTAA 2 MTAP7.5 
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TRCN0000238987 NM_026869.2-287s21c1 CDS PYGO2 NM_026869 Yes 3T3-L1 0.86 GATCATCTGGTCGCTTCTAAC 2 PYGO2.1 
TRCN0000238988 NM_026869.2-225s21c1 CDS PYGO2 NM_026869 Yes 3T3-L1 0.76 ATACTCAGGGTCCTGCATATT 2 PYGO2.2 
TRCN0000238989 NM_026869.2-1654s21c1 3UTR PYGO2 NM_026869 Yes 3T3-L1 0.8 CCAACACCCGTGCCTACAATA 2 PYGO2.3 
TRCN0000238990 NM_026869.2-1070s21c1 CDS PYGO2 NM_026869 Yes 3T3-L1 0.67 GCCTGCCGTAGTGAGGTAAAT 2 PYGO2.4 
TRCN0000257050 NM_026869.2-1287s21c1 CDS PYGO2 NM_026869 Yes 3T3-L1 0.59 ACGATGGGTGACTCTAGTACC 2 PYGO2.5 
TRCN0000329174 NM_011603.5-716s21c1 CDS TBPL1 NM_011603 Yes 3T3-L1 0.81 AGATCCGTTTGCCAGAATTTA 2 TBPL1.1 
TRCN0000329247 NM_011603.5-535s21c1 CDS TBPL1 NM_011603 Yes 3T3-L1 0.62 CCTAGAATTACAGCTACAATT 2 TBPL1.2 
TRCN0000329248 NM_011603.5-791s21c1 CDS TBPL1 NM_011603 Yes 3T3-L1 0.82 GCTATCGGATAAAGTCTCTAA 2 TBPL1.3 
TRCN0000375313 NM_011603.5-498s21c1 CDS TBPL1 NM_011603 Yes 3T3-L1 0.65 GCGTGATGTTGGGAAAGTATT 2 TBPL1.4 
TRCN0000375314 NM_011603.5-1310s21c1 3UTR TBPL1 NM_011603 Yes 3T3-L1 0.75 GGGCACCAAAGAACCTGTAAA 2 TBPL1.5 
           TRCN0000247807 NM_011363.2-2184s21c1 CDS SH2B1 NM_011363 Yes Hepa 1-6 0.82 GCATGCTCTCTCGACTCAAAG 2 SH2B1.1 
TRCN0000247808 NM_011363.2-2322s21c1 CDS SH2B1 NM_011363 Yes Hepa 1-6 0.65 ACCTGCGCTTGTCACTAAATG 2 SH2B1.2 
TRCN0000247809 NM_011363.2-3164s21c1 3UTR SH2B1 NM_011363 Yes Hepa 1-6 0.61 AGGTTCATGAGCCCTGTTAAG 2 SH2B1.3 
TRCN0000247810 NM_011363.2-1221s21c1 CDS SH2B1 NM_011363 Yes Hepa 1-6 0.59 TTGGTAGGGCATTGGCTAATG 2 SH2B1.4 
TRCN0000247811 NM_011363.2-1553s21c1 CDS SH2B1 NM_011363 Yes Hepa 1-6 0.81 AGCATTCCCTGCTCTACTATT 2 SH2B1.5 
TRCN0000336125 NM_011650.3-252s21c1 CDS TSN NM_011650 Yes NIH/3T3 0.61 AGAACATTTCAGTACAGTAAA 2 TSN.1 
TRCN0000336126 NM_011650.3-209s21c1 CDS TSN NM_011650 Yes NIH/3T3 0.73 GTACTGGATTTCAGGACATTC 2 TSN.2 
TRCN0000336148 NM_011650.3-478s21c1 CDS TSN NM_011650 
 
NA GAAGATTATCTCTCAGGAGTT 2 TSN.3 
TRCN0000336183 NM_011650.3-421s21c1 CDS TSN NM_011650 Yes NIH/3T3 0.7 GTTACAGAGATTCTTGGCATT 2 TSN.4 
TRCN0000336185 NM_011650.3-990s21c1 3UTR TSN NM_011650 Yes NIH/3T3 0.74 TGCCGTGTTGTCGTCGTATTA 2 TSN.5 
           TRCN0000306512 NM_019812.2-1370s21c1 CDS SIRT1 NM_019812 Yes Hepa 1-6 0.94 AGTGAGACCAGTAGCACTAAT 2 SIRT1.1 
TRCN0000306518 NM_019812.2-2617s21c1 3UTR SIRT1 NM_019812 
 
NA CTAGACCAAAGAATGGTATTT 2 SIRT1.2 
TRCN0000326966 NM_019812.2-921s21c1 CDS SIRT1 NM_019812 Yes Hepa 1-6 0.93 GCCATGTTTGATATTGAGTAT 2 SIRT1.3 
TRCN0000327027 NM_019812.2-1944s21c1 CDS SIRT1 NM_019812 Yes Hepa 1-6 0.86 GAGGGTAATCAATACCTGTTT 2 SIRT1.4 
TRCN0000327028 NM_019812.2-1659s21c1 CDS SIRT1 NM_019812 
 
NA CCTGAAAGAACTGTACCACAA 2 SIRT1.5 
TRCN0000231561 NM_011696.1-243s21c1 CDS VDAC3 NM_011696 Yes Hepa 1-6 0.83 GGCAACCTAGAGACCAAATAT 2 VDAC3.1 
TRCN0000231562 NM_011696.1-367s21c1 CDS VDAC3 NM_011696 Yes Hepa 1-6 0.67 TGACTCTTGATACCATATTTG 2 VDAC3.2 
TRCN0000231563 NM_011696.1-450s21c1 CDS VDAC3 NM_011696 Yes Hepa 1-6 0.82 CTCGGCAGTAATGTTGATATA 2 VDAC3.3 
TRCN0000231564 NM_011696.1-613s21c1 CDS VDAC3 NM_011696 Yes Hepa 1-6 0.85 AGCTGCATACTCACGTGAATG 2 VDAC3.4 
TRCN0000231565 NM_011696.1-1149s21c1 3UTR VDAC3 NM_011696 Yes Hepa 1-6 0.93 TTGAGTTCTGCAGAGTTAATT 2 VDAC3.5 
           TRCN0000352166 NM_007385.2-64s21c1 CDS APOC4 NM_007385 
 
NA GACCTGCCATCAGTCTCCCTT 2 APOC4.1 
TRCN0000352168 NM_007385.2-278s21c1 CDS APOC4 NM_007385 
 
NA CCTACTATGAAGATCACCTGA 2 APOC4.2 
TRCN0000352241 NM_007385.2-101s21c1 CDS APOC4 NM_007385 
 
NA TCAGCTTTGTAGCATCCATGT 2 APOC4.3 
TRCN0000363992 NM_007385.2-252s21c1 CDS APOC4 NM_007385 
 
NA TGGAGCTGTCCAGGGCTTTAT 2 APOC4.4 
TRCN0000376019 NM_007385.2-212s21c1 CDS APOC4 NM_007385 
 
NA TGACCAGAACCAGGGACAGAT 2 APOC4.5 
TRCN0000376083 NM_007385.2-117s21c1 CDS APOC4 NM_007385 
 
NA CATGTCTACAGAAAGCCTGAG 2 APOC4.6 
TRCN0000247072 NM_029667.2-530s21c1 3UTR LCE1I NM_029667 Yes Hepa 1-6 0.97 TGAGGAAGACTTCAGACAAAT 2 LCE1I.1 
TRCN0000247073 NM_029667.2-191s21c1 CDS LCE1I NM_029667 
 
NA GTGTCTTCCTGCTGTAGCTTG 2 LCE1I.2 
TRCN0000247074 NM_029667.2-549s21c1 3UTR LCE1I NM_029667 
 
NA ATAGTGCAGGAGGAGCACATG 2 LCE1I.3 
TRCN0000247075 NM_029667.2-561s21c1 3UTR LCE1I NM_029667 
 
NA GAGCACATGCTCAGAAGATTC 2 LCE1I.4 
TRCN0000247076 NM_029667.2-359s21c1 CDS LCE1I NM_029667 
 
NA AGCTCTGGATGCTGTAGCAGT 2 LCE1I.5 
TRCN0000335079 NM_010809.1-1479s21c1 CDS MMP3 NM_010809 Yes 3T3-L1 0.95 CCCACATATTGAAGAGCAATA 2 MMP3.1 
TRCN0000335080 NM_010809.1-1615s21c1 3UTR MMP3 NM_010809 Yes 3T3-L1 0.96 GCAGAACCAAACAGGAGCTAT 2 MMP3.2 
TRCN0000348408 NM_010809.1-1445s21c1 CDS MMP3 NM_010809 
 
NA CAGTTGGAATTTGACCCAAAT 2 MMP3.3 
TRCN0000348486 NM_010809.1-1184s21c1 CDS MMP3 NM_010809 Yes 3T3-L1 0.61 GAGCTAGCAGGTTATCCTAAA 2 MMP3.4 
TRCN0000250833 NM_009136.3-459s21c1 CDS SCRG1 NM_009136 
 
NA AGATGTCTTCTTTGGACCAAA 2 SCRG1.1 
TRCN0000250834 NM_009136.3-423s21c1 CDS SCRG1 NM_009136 Yes B16-F0 0.94 CTACTGCAACTTCAGCGAACT 2 SCRG1.2 
TRCN0000250835 NM_009136.3-521s21c1 3UTR SCRG1 NM_009136 Yes B16-F0 0.91 CCTTGCACTCTGGAGAACATG 2 SCRG1.3 
TRCN0000250836 NM_009136.3-308s21c1 CDS SCRG1 NM_009136 Yes B16-F0 0.89 AGTTGCTAAAGGATCGCAATT 2 SCRG1.4 
TRCN0000379710 NM_009308.3-739s21c1 CDS SYT4 NM_009308 
 
NA ACTTCGAGAAGAAAGCATTTG 2 SYT4.1 
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TRCN0000381498 NM_009308.3-481s21c1 CDS SYT4 NM_009308 
 
NA AGAGTGAAGTGAAGGGTAAAG 2 SYT4.2 
TRCN0000381737 NM_009308.3-1196s21c1 CDS SYT4 NM_009308 
 
NA ATCTGATGTGTCTGGACTTTC 2 SYT4.3 
TRCN0000382380 NM_009308.3-388s21c1 CDS SYT4 NM_009308 
 
NA AGACTCCTCCATACAAGTTTG 2 SYT4.4 
TRCN0000382514 NM_009308.3-1393s21c1 CDS SYT4 NM_009308 
 
NA GATCCCGAAATGAGGTGATTG 2 SYT4.5 
TRCN0000303144 NM_011575.2-129s21c1 CDS TFF3 NM_011575 
 
NA CAATGTATGGTGCCGGCAAAT 2 TFF3.1 
TRCN0000303214 NM_011575.2-172s21c1 CDS TFF3 NM_011575 
 
NA CCTCTGTCACATCGGAGCAGT 2 TFF3.2 
TRCN0000303215 NM_011575.2-236s21c1 CDS TFF3 NM_011575 
 
NA GCCCTGGTGCTTCAAACCTCT 2 TFF3.3 
TRCN0000303219 NM_011575.2-212s21c1 CDS TFF3 NM_011575 
 
NA CTTTGACTCCAGTATCCCAAA 2 TFF3.4 
TRCN0000331879 NM_011575.2-89s21c1 CDS TFF3 NM_011575 
 
NA CTCTGGGATAGCTGCAGATTA 2 TFF3.5 
TRCN0000313482 NM_009452.2-838s21c1 3UTR TNFSF4 NM_009452 
 
NA TTCCTCACTCAGGGATATTTA 2 TNFSF4.1 
TRCN0000349384 NM_009452.2-411s21c1 CDS TNFSF4 NM_009452 
 
NA GCAGAACAATTCGGTTGTCAT 2 TNFSF4.2 
TRCN0000349385 NM_009452.2-543s21c1 CDS TNFSF4 NM_009452 
 
NA CGATGGTCGAAGGATTGTCTT 2 TNFSF4.3 
TRCN0000349440 NM_009452.2-363s21c1 CDS TNFSF4 NM_009452 
 
NA GCAACTATTCATCAGCTCATA 2 TNFSF4.4 
TRCN0000349887 NM_009452.2-631s21c1 CDS TNFSF4 NM_009452 
 
NA TGCGAACACCTCCAGATAAAT 2 TNFSF4.5 
TRCN0000419335 NM_031202.2-1939s21c1 3UTR TYRP1 NM_031202 
 
NA ACACAGCTGTCAACCGTATTT 2 TYRP1.1 
TRCN0000432060 NM_031202.2-809s21c1 CDS TYRP1 NM_031202 
 
NA TGAGAACATTTCCGTTTATAA 2 TYRP1.2 
TRCN0000440816 NM_031202.2-352s21c1 CDS TYRP1 NM_031202 
 
NA CACGAGAGTGTGCCAATATTG 2 TYRP1.3 
TRCN0000336014 NM_011515.4-321s21c1 CDS VAMP7 NM_011515 Yes Hepa 1-6 0.56 TTTGTATCACTGATGATGATT 2 VAMP7.1 
TRCN0000336075 NM_011515.4-524s21c1 CDS VAMP7 NM_011515 Yes Hepa 1-6 0.92 GCACAAGTGGATGAACTGAAA 2 VAMP7.2 
TRCN0000336077 NM_011515.4-400s21c1 CDS VAMP7 NM_011515 
 
NA TTACGGTTCAAGAGCACAAAC 2 VAMP7.3 
TRCN0000353291 NM_011515.4-934s21c1 3UTR VAMP7 NM_011515 
 
NA CTTTGCCTGTCATATAGTTTG 2 VAMP7.4 
TRCN0000353419 NM_011515.4-422s21c1 CDS VAMP7 NM_011515 
 
NA GCACTTCCTTATGCTATGAAT 2 VAMP7.5 
TRCN0000380436 NM_011515.4-467s21c1 CDS VAMP7 NM_011515 
 
NA GCACAACTGAAGCATCACTCT 2 VAMP7.6 
TRCN0000380733 NM_011515.4-493s21c1 CDS VAMP7 NM_011515 
 
NA TAAGAGCCTAGACAAAGTGAT 2 VAMP7.7 
Supplemental Table 2.1: shRNA pool design for pilot pool
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TRC Id Clone Name Region Gene RefSeq Id Validated Cell line 
Validate 
Knockdown 
Target Seq TRC Version shRNA ID 
TRCN0000091848 NM_025271.1-439s1c1 CDS ACTL7B NM_025271 
   
CCAGAACATCTGGGAGTACAT 1 Actl7b.1 
TRCN0000091849 NM_025271.1-270s1c1 CDS ACTL7B NM_025271 
   
CCACCTATTTCATCTCCTCTA 1 Actl7b.2 
TRCN0000091850 NM_025271.1-269s1c1 CDS ACTL7B NM_025271 
   
CCCACCTATTTCATCTCCTCT 1 Actl7b.3 
TRCN0000091851 NM_025271.1-607s1c1 CDS ACTL7B NM_025271 
   
GCTGCTGTCCATCTACTCATA 1 Actl7b.4 
TRCN0000091852 NM_025271.1-608s1c1 CDS ACTL7B NM_025271 
   
CTGCTGTCCATCTACTCATAT 1 Actl7b.5 
TRCN0000081088 XM_129951.4-1743s1c1 3UTR ALPI XM_129951 
   
CCATAGATTTCCTGAGCCCAA 1 Alpi.1 
TRCN0000081089 XM_129951.4-967s1c1 CDS ALPI XM_129951 
   
CCACAAGGCTTCTACCTCTTT 1 Alpi.2 
TRCN0000081090 XM_129951.4-1213s1c1 CDS ALPI XM_129951 
   
GACAAATCCTACACCTCCATT 1 Alpi.3 
TRCN0000081091 XM_129951.4-861s1c1 CDS ALPI XM_129951 
   
CCTCTTTGAGCCAACAGAAAT 1 Alpi.4 
TRCN0000081092 XM_129951.4-45s1c1 CDS ALPI XM_129951 
   
CCATCTGTCCTTTGGTATCAT 1 Alpi.5 
TRCN0000106366 NM_009420.1-713s1c1 CDS CRISP2 NM_009420 
   
GCCATTACTGTCCTATGGGTA 1 Crisp2.1 
TRCN0000106368 NM_009420.1-286s1c1 CDS CRISP2 NM_009420 
   
CCAGACTTTACTTCTTTGTTA 1 Crisp2.2 
TRCN0000106369 NM_009420.1-776s1c1 CDS CRISP2 NM_009420 
   
CTTGTGCTAGTTGTCCCAATA 1 Crisp2.3 
TRCN0000173792 NM_010352.1-1121s1c1 3UTR GSG1 NM_010352 
   
CGCTCTGTCTCTGAAGCTATT 1 Gsg1.1 
TRCN0000175281 NM_010352.1-1160s1c1 3UTR GSG1 NM_010352 
   
CAGGACAAAGAATTTCAACAA 1 Gsg1.2 
TRCN0000175307 NM_010352.1-477s1c1 CDS GSG1 NM_010352 
   
CGTTTCATTGAACTCACACCA 1 Gsg1.3 
TRCN0000175876 NM_010352.1-861s1c1 CDS GSG1 NM_010352 
   
GAGACCACACTCTTGGAATTA 1 Gsg1.4 
TRCN0000193913 NM_010352.1-179s1c1 CDS GSG1 NM_010352 
   
CTTCATTTCTGCCATCCTCAA 1 Gsg1.5 
TRCN0000103220 NM_010360.1-449s1c1 CDS GSTM5 NM_010360 Yes Hepa 1-6 0.91 GCTACAATTCTAACCACGAAA 1 Gstm5.1 
TRCN0000103221 NM_010360.1-507s1c1 CDS GSTM5 NM_010360 Yes Hepa 1-6 0.96 GCTGAAACAATTCTCATTGTT 1 Gstm5.2 
TRCN0000103222 NM_010360.1-720s1c1 CDS GSTM5 NM_010360 Yes Hepa 1-6 0.93 GATGCCAATCAATAACAAGAT 1 Gstm5.3 
TRCN0000103223 NM_010360.1-593s1c1 CDS GSTM5 NM_010360 Yes Hepa 1-6 0.95 TCTTGGATCAGAACCGTATAT 1 Gstm5.4 
TRCN0000103224 NM_010360.1-592s1c1 CDS GSTM5 NM_010360 Yes Hepa 1-6 0.87 GTCTTGGATCAGAACCGTATA 1 Gstm5.5 
TRCN0000251025 NM_025731.2-794s21c1 CDS HRASLS5 NM_025731 
   
TTGTCAATGACCTCAGATATG 2 Hrasls5.1 
TRCN0000251026 NM_025731.2-407s21c1 CDS HRASLS5 NM_025731 
   
AGCTGATTCCAACATCAAATT 2 Hrasls5.2 
TRCN0000251027 NM_025731.2-518s21c1 CDS HRASLS5 NM_025731 
   
ATGAACATTGGGCCATCTATG 2 Hrasls5.3 
TRCN0000251028 NM_025731.2-310s21c1 CDS HRASLS5 NM_025731 
   
CTCAAGCAAGACCGCCGATTA 2 Hrasls5.4 
TRCN0000251029 NM_025731.2-755s21c1 CDS HRASLS5 NM_025731 
   
TAGTTCAGTACAGCCTAATTG 2 Hrasls5.5 
TRCN0000317640 NM_010787.1-545s21c1 CDS MEA1 NM_010787 Yes NIH/3T3 0.97 GTGGGAAGATGTGGTACAGAA 2 Mea1.1 
TRCN0000317719 NM_010787.1-192s21c1 CDS MEA1 NM_010787 Yes NIH/3T3 0.93 AGCAGTGAAGAACCCGAGGAA 2 Mea1.2 
TRCN0000317720 NM_010787.1-453s21c1 CDS MEA1 NM_010787 Yes NIH/3T3 0.81 GAACATGTAGAGCTGGTGAAA 2 Mea1.3 
TRCN0000317721 NM_010787.1-658s21c1 3UTR MEA1 NM_010787 Yes NIH/3T3 0.86 GACTAACAACTCTGGTCTTAA 2 Mea1.4 
TRCN0000319526 NM_010787.1-420s21c1 CDS MEA1 NM_010787 Yes NIH/3T3 0.98 TTGAGCAGCCACAGCTCTATC 2 Mea1.5 
TRCN0000336483 NM_018870.3-309s21c1 CDS PGAM2 NM_018870 Yes NIH/3T3 0.61 TTGGACCATCCTGGATGTTAC 2 Pgam2.1 
TRCN0000336553 NM_018870.3-134s21c1 CDS PGAM2 NM_018870 
   
TTCGCCACGGTGAGAGCTTAT 2 Pgam2.2 
TRCN0000336554 NM_018870.3-387s21c1 CDS PGAM2 NM_018870 
   
TGGCCTCACAGGCCTCAATAA 2 Pgam2.3 
TRCN0000336556 NM_018870.3-637s21c1 CDS PGAM2 NM_018870 
   
GCTGGCCAGAGAGTGCTTATT 2 Pgam2.4 
TRCN0000375078 NM_018870.3-476s21c1 CDS PGAM2 NM_018870 
   
CACCACCCATGGATGAGAAAC 2 Pgam2.5 
TRCN0000375079 NM_018870.3-558s21c1 CDS PGAM2 NM_018870 Yes NIH/3T3 0.84 GCCTACCTGTGAAAGTCTCAA 2 Pgam2.6 
TRCN0000379130 NM_018870.3-446s21c1 CDS PGAM2 NM_018870 
   
AGATCTGGAGGCGTTCCTTTG 2 Pgam2.7 
TRCN0000071228 NM_008892.1-2630s1c1 CDS POLA1 NM_008892 
   
CCTGGATTTCAACAGTTTATA 1 Pola1.1 
TRCN0000071229 NM_008892.1-1583s1c1 CDS POLA1 NM_008892 Yes Hepa 1-6 0.96 GCCAATCAGTTGGTGTAAATT 1 Pola1.2 
TRCN0000071230 NM_008892.1-3970s1c1 CDS POLA1 NM_008892 Yes Hepa 1-6 0.76 CCAGTTTGTATCGTTGCAGTA 1 Pola1.3 
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TRCN0000071231 NM_008892.1-279s1c1 CDS POLA1 NM_008892 Yes Hepa 1-6 0.66 CGTCAGGATGATGACTGGATT 1 Pola1.4 
TRCN0000071232 NM_008892.1-2766s1c1 CDS POLA1 NM_008892 Yes Hepa 1-6 0.62 CCAAACTTAGAGATGGGCATT 1 Pola1.5 
TRCN0000111395 NM_145480.1-928s1c1 CDS RFC4 NM_145480 Yes B16-F0 0.75 GCTGTGGTAAAGAACCTCATA 1 Rfc4.1 
TRCN0000111396 NM_145480.1-772s1c1 CDS RFC4 NM_145480 Yes B16-F0 0.83 CGGAAAGCCATCACATTTCTT 1 Rfc4.2 
TRCN0000111397 NM_145480.1-868s1c1 CDS RFC4 NM_145480 Yes B16-F0 0.84 GCTGCAACCATTGATGGAATA 1 Rfc4.3 
TRCN0000111398 NM_145480.1-658s1c1 CDS RFC4 NM_145480 Yes B16-F0 0.93 CCTCTGTCAGATAAGATTCAA 1 Rfc4.4 
TRCN0000111399 NM_145480.1-479s1c1 CDS RFC4 NM_145480 Yes B16-F0 0.87 GTCCTCCCTTTAAGATTGTAA 1 Rfc4.5 
TRCN0000247868 NM_030207.2-636s21c1 CDS SFI1 NM_030207 
   
ATGAGGAAGAGGTTCCGAATA 2 Sfi1.1 
TRCN0000247869 NM_030207.2-1674s21c1 CDS SFI1 NM_030207 
   
ACATTAGAGAAGCAAGTATTT 2 Sfi1.2 
TRCN0000247870 NM_030207.2-2304s21c1 CDS SFI1 NM_030207 
   
GTTACTTCAGTGCAGATATAT 2 Sfi1.3 
TRCN0000247871 NM_030207.2-695s21c1 CDS SFI1 NM_030207 
   
CTGGAAGTCCTGGTTGATATA 2 Sfi1.4 
TRCN0000247872 NM_030207.2-1547s21c1 CDS SFI1 NM_030207 
   
GGCCAGAGCAGATGGTCATTT 2 Sfi1.5 
TRCN0000306509 NM_011449.1-341s21c1 CDS SPA17 NM_011449 Yes Hepa 1-6 0.97 TGTGAACAAGAATTAGCTAAG 2 Spa17.1 
TRCN0000306510 NM_011449.1-371s21c1 CDS SPA17 NM_011449 Yes Hepa 1-6 0.91 AGAGAAGAAACACCAGTCACT 2 Spa17.2 
TRCN0000306511 NM_011449.1-394s21c1 CDS SPA17 NM_011449 Yes Hepa 1-6 0.88 CTTCGAGGAGTCTACTGAGGA 2 Spa17.3 
TRCN0000326953 NM_011449.1-187s21c1 CDS SPA17 NM_011449 Yes Hepa 1-6 0.5 ACCGGACAATATACCAGCTTT 2 Spa17.4 
TRCN0000327012 NM_011449.1-295s21c1 CDS SPA17 NM_011449 Yes Hepa 1-6 0.74 CTTCTATAACAACCACGCATT 2 Spa17.5 
TRCN0000196151 NM_133711.2-926s1c1 3UTR SPATA4 NM_133711 
   
GTGAAGGACATGGAGGAAGTA 1 Spata4.1 
TRCN0000215431 NM_133711.3-455s1c1 CDS SPATA4 NM_133711 
   
GGAGATTTACACTTTACTAAC 1 Spata4.2 
TRCN0000215604 NM_133711.3-603s1c1 CDS SPATA4 NM_133711 
   
GAACTACTAAGCAATCCTAAT 1 Spata4.3 
TRCN0000215867 NM_133711.3-477s1c1 CDS SPATA4 NM_133711 
   
CATCAAGAAATTAGAAGTATC 1 Spata4.4 
TRCN0000120437 NM_013686.1-821s1c1 CDS TCP1 NM_013686 
   
CCTGAGAAATTGGACCAAATT 1 Tcp1.1 
TRCN0000120438 NM_013686.1-1220s1c1 CDS TCP1 NM_013686 
   
CGCTCTTTACATGATGCTCTT 1 Tcp1.2 
TRCN0000120439 NM_013686.1-617s1c1 CDS TCP1 NM_013686 Yes Hepa 1-6 0.94 CGCTATCCAATCAATTCTGTT 1 Tcp1.3 
TRCN0000120440 NM_013686.1-395s1c1 CDS TCP1 NM_013686 
   
ACATCAGTTATTAGTGGCTAT 1 Tcp1.4 
TRCN0000120441 NM_013686.1-1397s1c1 CDS TCP1 NM_013686 
   
CCTAATACACTGGCAGTGAAT 1 Tcp1.5 
TRCN0000106380 NM_013687.2-1698s1c1 CDS TCP11 NM_013687 
   
CCCGTATTACACCGAGATCTT 1 Tcp11.1 
TRCN0000106381 NM_013687.2-1545s1c1 CDS TCP11 NM_013687 
   
GCGTATACACTTGTTCCTCAA 1 Tcp11.2 
TRCN0000106382 NM_013687.2-732s1c1 CDS TCP11 NM_013687 
   
CTCCTACCTCTCCAAGTATAT 1 Tcp11.3 
TRCN0000106383 NM_013687.2-460s1c1 CDS TCP11 NM_013687 
   
CTTGATTGTCAGTTGGAAGAA 1 Tcp11.4 
TRCN0000106384 NM_013687.2-1180s1c1 CDS TCP11 NM_013687 
   
GAAGAGTTTCCTGAAACCCTA 1 Tcp11.5 
TRCN0000346802 NM_025752.2-631s21c1 CDS 4933411K16RIK NM_025752 
   
TCCACAACTCACCGTCGTAAA 2 4933411K16Rik.1 
TRCN0000346863 NM_025752.2-281s21c1 CDS 4933411K16RIK NM_025752 
   
CAAATGACAGCTGGATCAAAT 2 4933411K16Rik.2 
TRCN0000346865 NM_025752.2-840s21c1 CDS 4933411K16RIK NM_025752 
   
CAACCAGAGTCATCCCGTTTA 2 4933411K16Rik.3 
TRCN0000346866 NM_025752.2-1204s21c1 3UTR 4933411K16RIK NM_025752 
   
TAAGAGACTGCCAACCAAATT 2 4933411K16Rik.4 
TRCN0000346867 NM_025752.2-1064s21c1 CDS 4933411K16RIK NM_025752 
   
CAAGCCACCAGAGCCATAATC 2 4933411K16Rik.5 
TRCN0000177244 NM_027910.1-1376s1c1 CDS KLHDC3 NM_027910 Yes B16-F0 0.96 GAATTTGACCTCATAGATCAT 1 Klhdc3.1 
TRCN0000177891 NM_027910.1-736s1c1 CDS KLHDC3 NM_027910 
   
CGCCTTTGATGTCAATACTCA 1 Klhdc3.2 
TRCN0000178618 NM_027910.1-1142s1c1 CDS KLHDC3 NM_027910 Yes B16-F0 0.79 CATTCAGCCTTTGGCTACAAT 1 Klhdc3.3 
TRCN0000182094 NM_027910.1-823s1c1 CDS KLHDC3 NM_027910 Yes B16-F0 0.79 CCTGGGCAAGATCATGTACAT 1 Klhdc3.4 
TRCN0000200040 NM_027910.1-909s1c1 CDS KLHDC3 NM_027910 
   
CCATGACATGGGCTCTTGTTT 1 Klhdc3.5 
TRCN0000217511 NM_027910.2-1023s1c1 CDS KLHDC3 NM_027910 
   
GGCCATTTCATTCCAACAATG 1 Klhdc3.6 
TRCN0000176986 NM_175349.2-405s1c1 CDS LDHAL6B NM_175349 
   
GCCCTTGTTGATAATAATGAA 1 Ldhal6b.1 
TRCN0000177866 NM_175349.2-1264s1c1 3UTR LDHAL6B NM_175349 
   
CCCTTCTAAAGATACCGAAGA 1 Ldhal6b.2 
TRCN0000181671 NM_175349.2-150s1c1 CDS LDHAL6B NM_175349 
   
GTGAGTACAACCAGGGTAGAT 1 Ldhal6b.3 
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TRCN0000181693 NM_175349.2-1091s1c1 CDS LDHAL6B NM_175349 
   
CCAAGGTCTCTACGGAATCAA 1 Ldhal6b.4 
TRCN0000198493 NM_175349.2-266s1c1 CDS LDHAL6B NM_175349 
   
GACCGTGAAGGGTGAACTTAT 1 Ldhal6b.5 
TRCN0000216958 NM_175349.2-579s1c1 CDS LDHAL6B NM_175349 
   
CTGAATTTAGTCCAGCGAAAC 1 Ldhal6b.6 
TRCN0000082218 NM_027949.1-1760s1c1 3UTR PHF7 NM_027949 
   
CCCAGGACAGTGAGATACAAA 1 Phf7.1 
TRCN0000082219 NM_027949.1-1142s1c1 CDS PHF7 NM_027949 Yes Hepa 1-6 0.87 CGCAAGTGTATCCAGAAATAT 1 Phf7.2 
TRCN0000082220 NM_027949.1-1456s1c1 CDS PHF7 NM_027949 
   
CAGCAAGAAATGGGAATGTAA 1 Phf7.3 
TRCN0000082221 NM_027949.1-1087s1c1 CDS PHF7 NM_027949 
   
CCGAACAAGTGTTGAGAACAT 1 Phf7.4 
TRCN0000082222 NM_027949.1-739s1c1 CDS PHF7 NM_027949 
   
AGACAATCTTTGTGTCCATTA 1 Phf7.5 
TRCN0000024369 NM_026888.1-363s1c1 CDS PHKG2 NM_026888 Yes 3T3-L1 0.82 CGAGTCTTCTAGCTTCATGTT 1 Phkg2.1 
TRCN0000024370 NM_026888.1-1060s1c1 CDS PHKG2 NM_026888 Yes 3T3-L1 0.66 CCACTAACTAAGAATGCACTA 1 Phkg2.2 
TRCN0000024371 NM_026888.1-552s1c1 CDS PHKG2 NM_026888 Yes 3T3-L1 0.59 CCTAGATGACAATATGCAGAT 1 Phkg2.3 
TRCN0000024372 NM_026888.1-783s1c1 CDS PHKG2 NM_026888 Yes 3T3-L1 0.62 CCAAATCCTGATGCTACGCAT 1 Phkg2.4 
TRCN0000024373 NM_026888.1-295s1c1 CDS PHKG2 NM_026888 Yes 3T3-L1 0.84 CGGCGAGAGATGCACATTCTT 1 Phkg2.5 
TRCN0000111365 NM_020022.2-1207s1c1 3UTR RFC2 NM_020022 Yes Hepa 1-6 0.9 CAGCTAGAACATGCTCACTTT 1 Rfc2.1 
TRCN0000111366 NM_020022.2-592s1c1 CDS RFC2 NM_020022 Yes Hepa 1-6 0.92 GCGTGTAATGCTTCAGACAAA 1 Rfc2.2 
TRCN0000111367 NM_020022.2-1003s1c1 CDS RFC2 NM_020022 Yes Hepa 1-6 0.85 CCGATGGCTGAATACTTGAAA 1 Rfc2.3 
TRCN0000111368 NM_020022.2-800s1c1 CDS RFC2 NM_020022 Yes Hepa 1-6 0.95 CCTTCTCAGGATTTGGCTATA 1 Rfc2.4 
TRCN0000111369 NM_020022.2-390s1c1 CDS RFC2 NM_020022 Yes Hepa 1-6 0.81 CCTGGAACTCAATGCCTCAAA 1 Rfc2.5 
TRCN0000042393 NM_009103.2-2730s1c1 3UTR RRM1 NM_009103 
   
GCCAGCTTTGATATTAGGAAT 1 Rrm1.1 
TRCN0000042394 NM_009103.2-402s1c1 CDS RRM1 NM_009103 
   
GCCGTCTCTAACTTGCACAAA 1 Rrm1.2 
TRCN0000042395 NM_009103.2-1134s1c1 CDS RRM1 NM_009103 
   
CGCGATCTCTTCTTTGCACTT 1 Rrm1.3 
TRCN0000042396 NM_009103.2-2345s1c1 CDS RRM1 NM_009103 Yes Hepa 1-6 0.9 GCAGGGTTTAAAGACTGGAAT 1 Rrm1.4 
TRCN0000042397 NM_009103.2-559s1c1 CDS RRM1 NM_009103 Yes Hepa 1-6 0.92 CCATTATCTATGACCGAGATT 1 Rrm1.5 
TRCN0000081553 NM_030237.2-1348s1c1 3UTR SPZ1 NM_030237 
   
CGCCAGAAGCAGATACAACTT 1 Spz1.1 
TRCN0000081554 NM_030237.2-1238s1c1 CDS SPZ1 NM_030237 
   
CCCGGATGTTTGCTTTACTAA 1 Spz1.2 
TRCN0000081555 NM_030237.2-874s1c1 CDS SPZ1 NM_030237 
   
GCCAGAACGAAACCCAAGAAA 1 Spz1.3 
TRCN0000081556 NM_030237.2-356s1c1 CDS SPZ1 NM_030237 
   
CCCACCACCAAAGAATAGCAT 1 Spz1.4 
TRCN0000081557 NM_030237.2-1015s1c1 CDS SPZ1 NM_030237 
   
CAGCCCTGCTAGAGAATGAAT 1 Spz1.5 
TRCN0000244259 NM_027592.2-153s21c1 CDS TAF9 NM_027592 Yes Hepa 1-6 0.99 ATCAGGCCTGAAGTACGTTAA 2 Taf9.1 
TRCN0000244260 NM_027592.2-560s21c1 CDS TAF9 NM_027592 Yes Hepa 1-6 0.98 GGATTGAGCAGTGGGTCAAAG 2 Taf9.2 
TRCN0000244261 NM_027592.2-626s21c1 3UTR TAF9 NM_027592 Yes Hepa 1-6 0.97 GTCCATCGTCCCAGATCTTAG 2 Taf9.3 
TRCN0000244387 NM_027592.2-251s21c1 CDS TAF9 NM_027592 Yes Hepa 1-6 0.98 ATAGGGTTGTCGATGAGTTAG 2 Taf9.4 
TRCN0000244388 NM_027592.2-328s21c1 CDS TAF9 NM_027592 Yes Hepa 1-6 0.98 CCCGAACGCTGGTTTCATATA 2 Taf9.5 
TRCN0000093944 NM_201645.1-2005s1c1 3UTR UGT1A1 NM_201645 
   
CCAGTGTTAGTCATTCTTCAT 1 Ugt1a1.1 
TRCN0000093945 NM_201645.1-548s1c1 CDS UGT1A1 NM_201645 
   
CCCACTGTGTACTTCTTGAAT 1 Ugt1a1.2 
TRCN0000093946 NM_201645.1-439s1c1 CDS UGT1A1 NM_201645 
   
GCTGCACAATGCCGAGTTTAT 1 Ugt1a1.3 
TRCN0000093947 NM_201645.1-133s1c1 CDS UGT1A1 NM_201645 
   
GAGGCTGTTAGTGTTCCCTAT 1 Ugt1a1.4 
TRCN0000093948 NM_201645.1-1174s1c1 CDS UGT1A1 NM_201645 
   
CCGTGGTATTTATGAAGGAAT 1 Ugt1a1.5 
TRCN0000362868 NM_053253.3-1209s21c1 CDS ZMYND10 NM_053253 
   
GCACCAGCTTCAGCACGTATT 2 Zmynd10.1 
TRCN0000362869 NM_053253.3-549s21c1 CDS ZMYND10 NM_053253 
   
CTTGGACCTAGTAGACTATTG 2 Zmynd10.2 
TRCN0000362870 NM_053253.3-670s21c1 CDS ZMYND10 NM_053253 
   
CAGGCGGAGATGATGGAATTT 2 Zmynd10.3 
TRCN0000362871 NM_053253.3-283s21c1 CDS ZMYND10 NM_053253 
   
GCCATCCTTGATGCAACTATC 2 Zmynd10.4 
TRCN0000352166 NM_007385.2-64s21c1 CDS APOC4 NM_007385 
  
NA GACCTGCCATCAGTCTCCCTT 2 Apoc4.1 
TRCN0000352241 NM_007385.2-101s21c1 CDS APOC4 NM_007385 
  
NA TCAGCTTTGTAGCATCCATGT 2 Apoc4.2 
TRCN0000363992 NM_007385.2-252s21c1 CDS APOC4 NM_007385 
  
NA TGGAGCTGTCCAGGGCTTTAT 2 Apoc4.3 
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TRCN0000376019 NM_007385.2-212s21c1 CDS APOC4 NM_007385 
  
NA TGACCAGAACCAGGGACAGAT 2 Apoc4.4 
TRCN0000376083 NM_007385.2-117s21c1 CDS APOC4 NM_007385 
  
NA CATGTCTACAGAAAGCCTGAG 2 Apoc4.5 
TRCN0000379710 NM_009308.3-739s21c1 CDS SYT4 NM_009308 
  
NA ACTTCGAGAAGAAAGCATTTG 2 Syt4.1 
TRCN0000381498 NM_009308.3-481s21c1 CDS SYT4 NM_009308 
  
NA AGAGTGAAGTGAAGGGTAAAG 2 Syt4.2 
TRCN0000382380 NM_009308.3-388s21c1 CDS SYT4 NM_009308 
  
NA AGACTCCTCCATACAAGTTTG 2 Syt4.3 
TRCN0000303144 NM_011575.2-129s21c1 CDS TFF3 NM_011575 
  
NA CAATGTATGGTGCCGGCAAAT 2 Tff3.1 
TRCN0000303214 NM_011575.2-172s21c1 CDS TFF3 NM_011575 
  
NA CCTCTGTCACATCGGAGCAGT 2 Tff3.2 
TRCN0000303215 NM_011575.2-236s21c1 CDS TFF3 NM_011575 
  
NA GCCCTGGTGCTTCAAACCTCT 2 Tff3.3 
TRCN0000303219 NM_011575.2-212s21c1 CDS TFF3 NM_011575 
  
NA CTTTGACTCCAGTATCCCAAA 2 Tff3.4 
TRCN0000331879 NM_011575.2-89s21c1 CDS TFF3 NM_011575 
  
NA CTCTGGGATAGCTGCAGATTA 2 Tff3.5 
SHC202 
       
CAACAAGATGAAGAGCACCAA 2 SHC202 
SHC216 
       
GCGCGATAGCGCTAATAATTT 2 SHC216 
Supplemental Table 2.2: shRNA pool design for predicted genes’ pool 
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Chapter 3 - Introduction 
While identification of fertility genes is important, the eventual goal of reproductive research is 
to fix the defects and restore fertility in patients. I envision two approaches to accomplish this 
goal. The first naïve, method is to deliver a plasmid expressing a transgene copy of the defective 
gene into the germ cells. The alternative approach is to fix the defective copy of the gene in the 
genome of the germ cells. 
 
Transgenic gene expression works by placing a copy of a gene (without introns) downstream of a 
ubiquitous promoter (e.g. CMV) and integrating it into the genome of a cell in the hope that this 
will compensate for the defective endogenous gene. Breeding a transgenic mouse with a 
knockout mouse has successfully rescued spermatogenesis in their progeny
1–3
. Direct delivery of 
a transgene expression construct has also successfully improved spermatogenesis in knockout 
mice
4–6
, but there have been many more reports about such methods inhibiting spermatogenesis 
instead
7–10
.  
 
Given the possibility of transgene delivery backfiring, I also explored the possibility of fixing the 
endogenous “broken” copy of the gene. CRISPR/cas9 is the most promising system at present. It 
uses a bacterial protein (cas9) to make double stranded DNA breaks based on a 26 base pair 
sequence targeting RNA. The endogenous mammalian DNA repair mechanisms then randomly 
repair the break by inserting or deleting random base pairs. If a homologous sequence is present, 
it will instead repair the broken DNA using the homolog as a template. By directly injecting the 
cas9 mRNA, targeting RNA, and single stranded homologous DNA into the nucleus of mouse 
embryos, you can make transgenic mice with relatively high efficiency
11,12
.  
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In this chapter, I will present the work I have done to adapt the direct DNA delivery technique 
described in the previous chapter to work with these two approaches. To perform transgene 
delivery, I selected mlh3 as the gene to study because there was an available knockout mouse 
that had been shown to have completely arrested spermatogenesis. I transfected the knockout and 
wild-type mouse testes with an expression plasmid that had a cDNA copy of mlh3 cloned into it. 
This was sufficient to determine the ability of transgene delivery to rescue spermatogenesis or if 
it had deleterious effects instead. For endogenous gene correction I used the all-in-one plasmid 
pioneered by Feng Zhang’s group11 to determine if it would be sufficient to cause double 
stranded breaks in the male germ cells, the first step in correcting defecting genes. 
 
Chapter 3 - Results 
Transgene delivery 
 
Figure 3.2: Expression of eGFP in testis after injection 
 
 
Figure 3.1: Plasmid for mlh3 rescue 
Sequence of plasmid is in Data 3.S1. 
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I injected a plasmid expressing mlh3 and eGFP into the testis of mlh3 lnockout mice and WT 
C57Bl6 mice (Figure 3.1) (I used GFP as a marker for mlh3 expression). While GFP expression 
in WT testis peaked 3 days after the injection, the expression rapidly decreased, becoming almost 
undetectable after 50 days (Figure 3.2). The injected mlh3 knockout mice were bred with WT 
female mice to see if any offspring could be produced. However, after 6 months of breeding 
there were no offspring. This data suggests that the plasmid was not effective at rescuing 
spermatogenesis.  
 
Figure 3.3: Morphology of testis after mlh3 expression plasmid injection 
The top row show the eGFP expression for the testis while the bottom row shows the hematoxylin 
and Eosin staining for the same sample. 
 
To explain why this would be the case I performed histology of the WT testis after plasmid 
injection at different time points. We found that eGFP expression was almost undetectable 10 
days after the injection and the morphology of the testis indicated severe impairment of 
spermatogenesis (Figure 3.3). This data seems to suggest that overexpression of mlh3 actually 
has a detrimental effect on spermatogenesis. 
98 
Endogenous gene repair 
Since my attempts at spermatogenesis rescue by transgene expression had failed, I worked on an 
alternative approach to rescue spermatogenesis instead. I hoped to accomplish this by ‘fixing’ the 
deleterious mutation in the affected gene to the wild-type sequence using the CRISPR/cas9 
system developed by Feng Zhang (Figure 3.4). 
 
Figure 3.4: CRISPR/cas9 plasmid system 
 
 
 
 
 
 
Figure 3.5: Immunofluorescence of cas9 plasmid 
injected testes 
Blue is DAPI stain, Green is eGFP (top two rows) 
or cas9 (bottom row) antibody 
 
The first benchmark we used was to detect if cas9 could be delivered and consistently expressed 
over a prolonged period. We were able to detect eGFP and cas9 expression even three weeks 
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after one injection of the plasmid into wild type mouse testes (Figure 3.5). Between 10%-30% of 
the tubules showed evidence of cas9/GFP expression. 
 
I then made four small guide RNA constructs against tyr (tyrosinase precursor), a gene when 
knocked out in mice produces a white coat color phenotype (v.s. normal black color). I called 
them tyr136, tyr184, tyr211 and tyr237 small guide RNAs after the nucleotide position in the 
gene where it targets. These guide RNAs were cloned into the cas9 plasmid and the constructs 
were injected into WT mouse testis which were then bred with female tyr KO mice from Jackson 
labs.  
 
Since no white offspring were produced (Table 3.1), I considered two possible explanations; 
either the four small guide RNA constructs are not effective or that it could be creating mutations 
at such a low rate that the breeding study was insufficient to detect the changes. To resolve this 
question I transfected the same constructs into N2a cell lines and WT mouse testes and used their 
genomic DNA to prepare a deep sequencing library across the tyr locus. I grouped substitutions, 
insertions, and deletions as mutations when calculating the mutation rate. 
 
 Tyr136 Tyr184 Tyr211 Tyr237 
Black offspring 36 8 31 27 
White offspring 0 0 0 0 
Table 3.1: Offspring coat colors from the injected WT X tyr KO cross 
Black/White offspring indicates that the directed mutation failed or succeeded respectively. 
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Figure 3.6: Mutation rate of tyr constructs in N2a cell line and mouse testes 
The x axis shows the coordinates of section of the tyr gene that was targeted, with a vertical line 
indicating the targeted cut site. The y axis indicates the mutation rate. 
 
The mutation rate of the constructs in the N2a cell line ranged between 8-28%. However, the 
exact same constructs had no detectable mutations in the testes (Figure 3.6). Since previous 
experiments show that cas9 is delivered and expressed in the testes for prolonged periods of 
time, I eliminated the possibility of it being a plasmid delivery or expression issue. 
 
Because in vitro cell line transfection is more efficient than in vivo testis transfection I 
considered that this might be a dosage issue. I took the tyr237 construct and injected it into WT 
mouse testes up to ten times, spaced three to four days apart, in order to boost the in vivo 
transfection rate. Furthermore, I also FACS sorted one WT testis that had undergone ten 
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injections to isolate a million eGFP positive and negative cells. This was performed to isolate the 
cells with cas9 expression to see if it would increase the sensitivity for detecting mutation rates. 
The samples’ genomic DNA was once again used to prepare a deep sequencing library to 
determine the mutation rate. 
 
I found that the mutation rate at the target site was undetectable under all conditions (Figure 
3.7). Although GFP positive cells appear to have an elevated mutation rate downstream of the 
target site, this is 
probably due to 
stochastic selection of 
cells elevating natural 
variants by chance 
rather than evidence of 
cas9 activity. 
 
 
 
 
Figure 3.7: Mutation rate of tyr237 cas9 constructs in mouse testes (Higher dosage) 
See Figure 3.6 for graph axis explanation 
 
Another possible explanation for why the cas9 constructs were not working is that male germ 
cells have some mechanism that inhibits cas9 function (Either an active pathway or DNA 
packing). I decided to use a mouse spermatocyte cell line, Gc2-spd as the model system to 
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answer this question. If this hypothesis is true, we would expect the mutation rate using the same 
constructs to be much lower than in the N2a cell line despite the higher transfection rate. 
 
There was a detectable mutation rate in the Gc2-spd cell line for all the constructs, but it was up 
to ten times lower than in the N2a cell lines, despite increasing the amount of DNA and 
transfection reagent (Figure 3.8). A previous attempt using identical DNA and transfection 
reagent amounts in the Gc2-spd cell as the N2a cells did not create any detectable mutation rate 
(Data not shown).  
 
This data suggests that there 
is some mechanism in the 
germ cell that inhibits cas9 
activity.  
 
 
 
 
 
 
 
 
Figure 3.8: Mutation rate of tyr cas9 constructs in Gc2-spd cell line 
See Figure 3.6 for graph axis explanation 
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Chapter 3 - Discussion 
Overexpressing transgenic copies of genes can have just as much deleterious consequences as 
knocking them out in the genome
7–10
. Studies that rescue fertility by transgenic expression 
attempt to ensure that not too many copies of the transgene are present in the genome, 
presumably to avoid the deleterious effects of massive oversexpression
5,6
. This suggests that a 
naïve transfection of a pool of transgenic genes is unlikely to boost spermatogenesis and might 
even cause detrimental effects. 
 
To fix infertility due to spermatogenesis problems, we should be fixing the endogenous ‘broken’ 
genes instead. I have shown that the previously presented low cost in vivo male germ cell 
transfection method cannot be used to work with the CRISPR/cas9 system. The guide RNA 
constructs also showed lower efficiency when transfected into a spermatocyte cell line compared 
to a neuronal cell line, despite an increase in the transfection reagents. 
 
Why did the tyr constructs work in the Gc2-spd cell line when it did not work in the testes? My 
hypothesis is that the Gc2-spd cell line contains proportionally more stem cells than the testis 
tissue does. Other groups have shown that it is possible to manipulate the genomes of 
spermatogonial stem cells
13
. My hypothesis is that if you can introduce cas9 before the cells 
develop into germ cells, it will be possible to edit their genomes.  
 
If I could increase the in vivo transfection rate it would increase the chances of delivering the 
CRISPR constructs into primordial germ cells, where they could work. To accomplish this, 
104 
future work will have to involve more technically challenging protocols such as efferent duct 
injection and/or lentivirus infection. 
 
If a working approach could be found that fixes spermatogenesis in mice via genetic engineering, 
we could also use the same system to make new transgenic animals for other disease models. 
More experiments will also be needed to ensure the safety and minimize off-target effects, but 
there is the potential to use the system to repair all sorts of genetic defects, not just the ones that 
affect fertility. 
 
 
Chapter 3 - Methods 
Plasmid cloning 
The mlh3 overexpression plasmid was cloned using the sequence obtained from Mammalian 
Gene Collection (MGC:100285) with the pCI mammalian expression plasmid as the backbone 
(Promega: E1731).  
CRISPR/cas9 constructs were cloned into the pX458 plasmid backbone (Addgene: 48138) 
following the previously published protocol
14
. Primers used for the constructs can be found in 
Table 3.S1. 
 
Cell line transfection 
N2a cells were maintained in Minimum Essential Media (MEM) supplemented with 10% Fetal 
Bovine Serum (FBS) until they reached 60% confluency in 6 well cell culture plates. Each well 
of cells was transfected with 1µg of plasmid DNA using 3.75µl of Lipofectamine® 3000 (Life 
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Technologies: L3000008). The cells were then incubated at 37°C for 2 days, with daily media 
replacement, before the genomic DNA was collected. 
Gc2-spd cells were treated the same way and the N2a cells, with the only change being each well 
was transfected with of 2.5µg of plasmid DNA and 7.5µl of Lipofectamine® 3000 instead. 
 Cell genomic DNA was extracted using DNeasy blood and Tissue Kit (Qiagen: 69504) using the 
manufacturer’s suggested protocol. 
 
DNA Library preparation 
Extracted genomic DNA was amplified using a Q5 hot-start high fidelity polymerase (NEB: 
M0493L) using the manufacturer’s protocol and custom primers (Table S2). This PCR product 
was purified using Minelute columns (Qiagen: 28004). The overhang from the custom primers 
was used to attach Illumina sequencing adapters and indices via a second round of PCR. This 
PCR product was purified using Agencourt AmPure XP beads (Beckman-Coulter: A63880) 
following the manufacturer’s protocol. Each library was run on a 3% agarose gel to ensure that 
the library size was around 300bp. Libraries from multiple samples were pooled and run on a 
single lane of Illumina MiSeq. 
 
Data Analysis 
Paired end reads were mapped to the mouse mm10 genome assembly using STAR
15
. Reads 
across the tyr locus was verified to make up more than 95% of the total reads in the sample. 
These reads were condensed using samtools’ mpileup command, using the –A option to increase 
the max depth to 2,000,000
16
. This data was then run through a custom analysis script to 
calculate and plot the mutation rate at each base pair in the locus. A mutation was classified as 
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any base at that position which did not match the reference genome, including insertions and 
deletions. 
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LOCUS       Exported               10252 bp ds-DNA    circular SYN 08-JAN-2015 
DEFINITION  . 
ACCESSION   . 
VERSION     . 
KEYWORDS    Untitled 
SOURCE      synthetic DNA construct 
  ORGANISM  synthetic DNA construct 
REFERENCE   1  (bases 1 to 10252) 
  AUTHORS   . 
  TITLE     Direct Submission 
  JOURNAL   Exported Thursday, Jan 08, 2015 from SnapGene Viewer 2.5.0 
            http://www.snapgene.com 
FEATURES             Location/Qualifiers 
     source          1..10252 
                     /organism="synthetic DNA construct" 
                     /mol_type="other DNA" 
     CDS    1..5481 
                     /codon_start=1 
                     /gene="Mlh3" 
                     /product="mutL homolog 3 (E coli)" 
                     /note="Mlh3" 
                     /note="color: #993366"; direction: RIGHT 
                     /db_xref="GI:51259774" 
                     /db_xref="GeneID:217716" 
                     /db_xref="MGI:1353455" 
                     /protein_id="AAH79861.1" 
                     /translation="MIRCLSDDVKTKLRSGLAISSLGQCVEELTLNSIDAEATCVAIRV 
NMETFQVQVIDNGLGMAGDDVEKVGNRYFTSKCHSVRDLENPAFYGFRGEALASIADMA 
GAVEISSKKNTTLKTFVKMFQNGKALATHEADLTRPSVGTTVTVYNLFYQFPVRRKSMD 
PRLEFEKVRQRVEALSLMHPSISFSLRNDVSGSMVLQLPKTKDICSRFCQIYGLGKSQK 
LREIRFKYKEFEFSGYISSEAHYNKNMQFLFVNRRLVLRTKLHKLIDFLLRKESIICRP 
KNGSASRQMNSSPRHRSASELHGIYVINVQCPFCEYDVCIEPAKTLIEFQSWDTVLICI 
QEGVKRFLKQEKLFVELSGEDIKEFNEDNGFSLFGTTLQTHVSTHEKCDQSSFREACNK 
ILDSYEMFNLQSKAVKRIATLENKTRQNPGDSETIRKKTVGSLYTDASDGPCYSKSVES 
VLQDSNNSAYLEPRVSEEEVAKTSHSGENEKWKKSFLENKTSGRIHETSPKMFSSPIQM 
HHLLEEREADLEMQTISSTVNVMAANIPQNNDIPSQLEKWKDAPEVGCQPLPFETTLLR 
VRGTQRKKERRKKEPSSRGRVNVFSYGQVKLCSTGFITHVVQSEHAKSTETEHSFKNYA 
RPGPVSAQETFGKRTHHAIETPDSSDLTSTLSKESSQPPNKRFCRTNTGYGTENKPVAT 
DDNLALFQESCKESHTDRLLPDASSFPWCRYVSDGCRKIDKRGSFKQVVRRKLSLRSQV 
GSLEKFKRQYGKVSSSLDTEKDNNTEVRTHLDPQNEPDVLLKDKSHLDMSDGCEITTVE 
 HSETCQPLSPILYPEKILFSKEDRLEQMPHLRESPITLEELSHCNRKADVEKSAASLAS 
KLSKLKDSEKEMQTVGMTGHTSELPDSNPSWKDNSQCTRLDLDFCELLKNKLEKIESDM 
LPMADSATEDGPINKNSELHPNNTTDDTEKPETPLLFPCNDSKISRDSDVLIRTSEQPT 
GNPDSVGKVIMSQVEDGIGSQGGVCPQGDESKARSCSKNEPNAHCMDWQQHFDVTLGRM 
VYINRMTGLSTFVAPTDDLHTACTKDLTTVAVDVLLGNDAVDAAAAAVSEPLQSLFSEW 
SNPVFARYPEVAVDVSSGQAESLAVKIHNVLYPYRFTKEMIHSVKVLQQVDNKFIACLM 
STRMDEDGRTGGNLLVLVDQHAAHERIRLEQLITDSYEKQDPQSAGRKKLLSSTIIPPL 
AITVSEEQRRLLRSYHKHLEDLGLELLFPDASDSLILVGKVPLCFVEREASELRRGRST 
VTKSIVEELIREQVELLQTTGGIQGTLPLTVQKVLASQACHGAIKFNDRLSLEESCRLI 
EALSLSQLPFQCAHGRPSMLPLADLDHLEQEKQVKPNLAKLRKMVRAWHLFGKTEQNLQ 
QPIRPCEPP" 
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     CDS             5493..5546 
                     /codon_start=1 
                     /product="2A peptide from Thosea asigna virus capsid  
                     protein" 
                     /note="T2A" 
                     /note="Eukaryotic ribosomes fail to insert a peptide bond  
                     between the Gly and Pro residues, yielding separate  
                     polypeptides." 
                     /translation="EGRGSLLTCGDVEENPGP" 
     CDS             5547..6260 
                     /codon_start=1 
                     /product="enhanced GFP" 
                     /note="EGFP" 
                     /note="mammalian codon-optimized" 
                     /translation="VSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK 
FICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDG 
NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKV 
NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLE 
FVTAAGITLGMDELYK" 
     polyA_signal    6308..6429 
                     /note="SV40 poly(A) signal" 
                     /note="SV40 polyadenylation signal" 
     rep_origin      6610..7065 
                     /direction=RIGHT 
                     /note="f1 ori" 
                     /note="f1 bacteriophage origin of replication; arrow  
                     indicates direction of (+) strand synthesis" 
     promoter        7397..7501 
                     /gene="bla" 
                     /note="AmpR promoter" 
     CDS             7502..8362 
                     /codon_start=1 
                     /gene="bla" 
                     /product="beta-lactamase" 
                     /note="AmpR" 
                     /note="confers resistance to ampicillin, carbenicillin, and 
                     related antibiotics" 
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYI 
ELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVEYS 
PVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRW 
EPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSA 
LPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGAS 
LIKHW" 
     rep_origin      8533..9121 
                     /direction=RIGHT 
                     /note="ori" 
                     /note="high-copy-number ColE1/pMB1/pBR322/pUC origin of  
                     replication" 
     enhancer        9332..9711 
                     /note="CMV enhancer" 
                     /note="human cytomegalovirus immediate early enhancer" 
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     promoter        9712..9915 
                     /note="CMV promoter" 
                     /note="human cytomegalovirus (CMV) immediate early  
                     promoter" 
     intron          10051..10183 
                     /note="chimeric intron" 
                     /note="chimera between introns from human beta-globin and  
                     immunoglobulin heavy chain genes" 
     promoter        10228..10246 
                     /note="T7 promoter" 
                     /note="promoter for bacteriophage T7 RNA polymerase" 
ORIGIN 
        1 ggcgcgccga attcggcacg agggtgagag ttgatggagg agattcgagg tgattatttt 
       61 ccagtcagag aaggaagcca gtgtctgcca ctccctccac atgtgtccct gccatgatca 
      121 ggtgtctatc agatgacgta aaaaccaagt tgcgttccgg tttagccata agctccttgg 
      181 gccagtgtgt tgaagaactt acccttaaca gtattgatgc tgaagcaaca tgtgtggcca 
      241 tcagagtgaa tatggaaacc ttccaagttc aagtgataga caatggactt gggatggcgg 
      301 gggacgatgt agagaaggtg ggaaaccggt attttactag taaatgccac tcagtgcggg 
      361 acttggagaa cccagcattt tatggcttcc gaggagaggc cttggcaagt atagccgaca 
      421 tggctggtgc tgtggagatt tcatccaaga aaaacacaac actgaaaacc tttgtgaaaa 
      481 tgtttcagaa tggaaaagcc cttgccaccc atgaggctga tttgaccaga ccaagtgtgg 
      541 ggactacagt aacggtctat aacctgtttt accagtttcc tgtgcggagg aaaagcatgg 
      601 atcctagact agagtttgag aaagttcggc agagggtaga agctctctca cttatgcacc 
      661 cctccatttc tttctctttg aggaacgatg tatctggatc catggttctt cagctcccta 
      721 aaaccaaaga catatgctct cgattctgtc aaatttacgg attgggcaag tcccaaaagt 
      781 taagagaaat acgttttaaa tacaaggaat ttgagttcag tggctacatc agctctgaag 
      841 cacactacaa taagaatatg cagtttttgt ttgtgaacag aagactagtt ttaagaacaa 
      901 agttgcataa acttattgac tttttattaa gaaaagaaag cattatatgc aggccaaaga 
      961 atggctctgc cagtaggcaa atgaattcaa gtcctcgaca ccgttctgcc tcagaactcc 
     1021 acgggatata tgtaatcaat gtgcagtgcc ctttctgtga gtatgatgtc tgcatagagc 
     1081 cagccaaaac tctgattgag tttcagagct gggataccgt gttgatttgt attcaggaag 
     1141 gagtaaaaag gtttttaaag caagaaaaat tatttgtaga attatcaggt gaagatatta 
     1201 aggaatttaa tgaagataat ggttttagtt tgtttggcac gactcttcag acacatgtgt 
     1261 ctactcatga gaagtgtgac cagagcagtt tccgggaagc gtgtaataaa attctggatt 
     1321 cctatgaaat gtttaatttg cagtcaaaag ctgtgaaaag aatagctact ctagaaaata 
     1381 aaaccagaca aaaccctggt gattcagaaa ctatcagaaa aaagacagtg ggctcattgt 
     1441 acacagatgc atcggatggc ccgtgctata gtaaatcggt agagtctgtt ttacaggaca 
     1501 gcaacaacag tgcttactta gaaccgaggg tgtcagaaga agaggtagcc aaaacatcac 
     1561 actccggaga aaatgagaaa tggaaaaaat cttttttgga aaataagact tcaggaagga 
     1621 tacatgaaac cagtccaaaa atgttttcaa gccccatcca aatgcatcac ctccttgagg 
     1681 agagagaggc agatctggaa atgcagacaa taagtagtac tgttaatgtc atggctgcca 
     1741 acattcccca aaataatgac attccgagtc aactggagaa atggaaagat gctcctgaag 
     1801 tggggtgcca acctctgcct tttgagacaa ccttattaag ggtacggggt actcagagga 
     1861 agaaggaaag aaggaaaaag gagcccagta gtcgtggaag agtaaatgtt tttagttatg 
     1921 gacaagttaa attatgctcc actggcttta taactcatgt agtacaaagt gagcacgcta 
     1981 aatcaactga aacagaacat tcatttaaaa attatgctcg acctggtcct gtaagtgccc 
     2041 aagaaacatt tggaaaaaga acacaccatg caattgagac tccagacagc agtgatttaa 
     2101 caagcacttt aagtaaagaa tccagtcaac cgcccaacaa aaggttttgc agaacaaata 
     2161 caggttacgg gacagagaac aaacctgtag caacagatga caacttggct ctttttcagg 
     2221 aaagctgtaa agaatcacac acagatcgcc ttttgcctga tgcatcctcc ttcccatggt 
     2281 gtagatatgt ttccgatggt tgtaggaaaa tagataaaag gggttccttc aaacaggtag 
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     2341 tccgtaggaa gctaagcttg cgttcacaag tagggtcttt agagaagttt aagaggcagt 
     2401 atgggaaggt cagcagttcc ctagatacag aaaaggataa taacactgaa gtcaggactc 
     2461 atcttgatcc tcaaaatgaa cccgatgttc ttctgaaaga caagagccac ttagatatgt 
     2521 ctgatggttg tgagatcact actgtggagc acagtgagac ttgtcaacca ttaagtccca 
     2581 tcctgtaccc agaaaaaatt ttattttcca aagaagatcg cttagaacag atgcctcatt 
     2641 tgagagaaag tcctataact ctggaagaat tatctcactg taacagaaaa gctgatgttg 
     2701 agaagtccgc tgcatcactg gcttctaaat tatccaaact aaaggattct gaaaaagaga 
     2761 tgcaaaccgt ggggatgaca ggtcatacta gtgaacttcc agattcaaat cccagttgga 
     2821 aagataatag ccagtgcact aggttagact tggatttttg tgaattatta aaaaacaaac 
     2881 ttgaaaaaat agagagtgat atgcttccaa tggcagattc tgccacagag gatggtccca 
     2941 tcaataaaaa cagtgaacta catcctaaca atacaacgga tgacacagag aaaccagaaa 
     3001 ctcctttgct gttcccctgt aatgattcta aaatcagcag agattcagat gttcttatca 
     3061 gaacttcaga acaacctaca ggaaaccctg actctgtcgg taaagtgata atgagtcagg 
     3121 tagaggatgg cattggcagc caaggtggag tctgtcccca gggtgatgaa tctaaggcaa 
     3181 gatcttgttc caaaaatgaa ccaaacgcac actgtatgga ttggcagcag cattttgatg 
     3241 taaccctggg aagaatggtt tacatcaaca gaatgacagg acttagcaca ttcgttgctc 
     3301 caactgacga ccttcatact gcttgtacta aagatctgac aactgtggct gtggatgtcc 
     3361 tgcttgggaa tgatgctgtg gatgctgctg ctgctgctgt cagtgaaccc cttcagtctc 
     3421 tgttttcaga atggagcaat ccagtgtttg ctcgataccc agaggttgct gttgatgtca 
     3481 gcagtggcca ggctgagagc ttagccgtta aaattcacaa cgtcctgtat ccctatcgct 
     3541 tcaccaaaga gatgattcac tcagtgaagg ttctccagca agtggataac aagtttattg 
     3601 cctgcttaat gagcacgagg atggatgagg atggccgaac aggtggaaac ctgttagtcc 
     3661 tggtggacca gcatgctgcc catgaacgca ttcgtttgga gcagcttatt actgattcct 
     3721 atgagaaaca agatccacaa agcgctggcc ggaagaaatt attgtcttcc acaataatcc 
     3781 ctccactggc aatcaccgtg tcagaggaac aaaggagact cttacggtct taccacaaac 
     3841 atttagaaga tctggggctt gagttgctct ttccagatgc tagtgattct ctgatcctgg 
     3901 tgggaaaagt gccgctctgc tttgtagaga gagaagctag tgagcttcga agaggacgct 
     3961 ctactgtgac taagagtatt gtggaggaat taattcgaga acaagtggag ctgctccaga 
     4021 ccacaggagg tatccaaggg acactgccac tgactgtcca gaaggtgttg gcctcccagg 
     4081 cctgccatgg ggctattaag tttaatgatc gtctgagcct agaagagagc tgccgcctca 
     4141 tcgaagctct gtccttgtcc cagctgccat ttcagtgtgc tcatgggaga ccctcaatgc 
     4201 tgcccttagc tgacctggac cacttggagc aggaaaaaca ggttaaaccc aaccttgcta 
     4261 aacttcgcaa aatggttcgt gcctggcatc tctttggaaa aacagagcag aacctgcagc 
     4321 agcctatacg tccttgtgag cctccatgag gagaggattc tggagtgtaa ggagacaagg 
     4381 gagtgccgtg catcccgagc aggagcagtg cagctgtggg caggtcggcg gccctgagcg 
     4441 ggctggcaca tcagtccccc tgagcagatg gagcaggcac gtgcactcaa gcctaagggt 
     4501 agtttatttc tttgcatcca tgcacacagg agcttgacat ataataccta tcttttgtaa 
     4561 gttgatttag tgataaaatg taatgatttt gtaattggtg agttggctta tgtttgaggg 
     4621 gcgcagctat tgtttttagc agttttcccc agcctctcag tttatattac gtgaggatgc 
     4681 taagccctaa gcgctggtct gctcttctct gagcccctgg ctctgcccct ccccatccat 
     4741 ttctcttttg catttgtctc cttcacttca tacctctgct tcttcacatt gtgctttaca 
     4801 gacttacggt gtttctctgc tcattataaa aatatttccc gccaggcagc ggtggctcac 
     4861 acctttagtc ccagtacttg ggaggcagag gcaggtggat ttctgatttc aaggccagcc 
     4921 tggtctgcaa agtgagttcc aggacagcca cagggctaca aagagaaacc ctgtctcaaa 
     4981 aaaaccaaaa caacaacaac aacaacaaaa cttcctgatg tcttccagag agactaaatt 
     5041 atattaggga ttaaaagtta tttatagctg ggtgtagtga catatacctg taatcctagt 
     5101 acctgggagg ctgagacaag tccgtgacag ggcaccattt gcctaggctg gatatatagc 
     5161 aagaccttga ctcaaaataa ataagtaaac tatagacaaa gagagacaca aagacagaat 
     5221 agagaaagtt tgaaaagaat ttttttaatt ctcttggtaa cctggctgtc ctggaactgg 
     5281 aactcagaga tccccctttg ctgcctccga gtgctgggat taacggtgcg cgccaccact 
     5341 gcctggcaag aaaaattaca accctgtccc tggttttttt gatagtctta ctggttttta 
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     5401 aaaccagagg tgaatgtttc tattctgaac taataaaaca ctaaaaaata aaaaaaaaaa 
     5461 aaaaaaaaaa aggctctctc agcggccgcg gagagggcag aggaagtctg ctaacatgcg 
     5521 gtgacgtcga ggagaatcct ggcccagtga gcaagggcga ggagctgttc accggggtgg 
     5581 tgcccatcct ggtcgagctg gacggcgacg taaacggcca caagttcagc gtgtccggcg 
     5641 agggcgaggg cgatgccacc tacggcaagc tgaccctgaa gttcatctgc accaccggca 
     5701 agctgcccgt gccctggccc accctcgtga ccaccctgac ctacggcgtg cagtgcttca 
     5761 gccgctaccc cgaccacatg aagcagcacg acttcttcaa gtccgccatg cccgaaggct 
     5821 acgtccagga gcgcaccatc ttcttcaagg acgacggcaa ctacaagacc cgcgccgagg 
     5881 tgaagttcga gggcgacacc ctggtgaacc gcatcgagct gaagggcatc gacttcaagg 
     5941 aggacggcaa catcctgggg cacaagctgg agtacaacta caacagccac aacgtctata 
     6001 tcatggccga caagcagaag aacggcatca aggtgaactt caagatccgc cacaacatcg 
     6061 aggacggcag cgtgcagctc gccgaccact accagcagaa cacccccatc ggcgacggcc 
     6121 ccgtgctgct gcccgacaac cactacctga gcacccagtc cgccctgagc aaagacccca 
     6181 acgagaagcg cgatcacatg gtcctgctgg agttcgtgac cgccgccggg atcactctcg 
     6241 gcatggacga gctgtacaag gaattctaac tagagctcgc tgatcacccg ggttcgagca 
     6301 gacatgataa gatacattga tgagtttgga caaaccacaa ctagaatgca gtgaaaaaaa 
     6361 tgctttattt gtgaaatttg tgatgctatt gctttatttg taaccattat aagctgcaat 
     6421 aaacaagtta acaacaacaa ttgcattcat tttatgtttc aggttcaggg ggagatgtgg 
     6481 gaggtttttt aaagcaagta aaacctctac aaatgtggta aaatcgataa ggatccgggc 
     6541 tggcgtaata gcgaagaggc ccgcaccgat cgcccttccc aacagttgcg cagcctgaat 
     6601 ggcgaatgga cgcgccctgt agcggcgcat taagcgcggc gggtgtggtg gttacgcgca 
     6661 gcgtgaccgc tacacttgcc agcgccctag cgcccgctcc tttcgctttc ttcccttcct 
     6721 ttctcgccac gttcgccggc tttccccgtc aagctctaaa tcgggggctc cctttagggt 
     6781 tccgatttag tgctttacgg cacctcgacc ccaaaaaact tgattagggt gatggttcac 
     6841 gtagtgggcc atcgccctga tagacggttt ttcgcccttt gacgttggag tccacgttct 
     6901 ttaatagtgg actcttgttc caaactggaa caacactcaa ccctatctcg gtctattctt 
     6961 ttgatttata agggattttg ccgatttcgg cctattggtt aaaaaatgag ctgatttaac 
     7021 aaaaatttaa cgcgaatttt aacaaaatat taacgcttac aatttcctga tgcggtattt 
     7081 tctccttacg catctgtgcg gtatttcaca ccgcatatgg tgcactctca gtacaatctg 
     7141 ctctgatgcc gcatagttaa gccagccccg acacccgcca acacccgctg acgcgccctg 
     7201 acgggcttgt ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg 
     7261 catgtgtcag aggttttcac cgtcatcacc gaaacgcgcg agacgaaagg gcctcgtgat 
     7321 acgcctattt ttataggtta atgtcatgat aataatggtt tcttagacgt caggtggcac 
     7381 ttttcgggga aatgtgcgcg gaacccctat ttgtttattt ttctaaatac attcaaatat 
     7441 gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag 
     7501 tatgagtatt caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc 
     7561 tgtttttgct cacccagaaa cgctggtgaa agtaaaagat gctgaagatc agttgggtgc 
     7621 acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc 
     7681 cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg cggtattatc 
     7741 ccgtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc agaatgactt 
     7801 ggttgagtac tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt 
     7861 atgcagtgct gccataacca tgagtgataa cactgcggcc aacttacttc tgacaacgat 
     7921 cggaggaccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgcct 
     7981 tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat 
     8041 gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc 
     8101 ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg 
     8161 ctcggccctt ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc 
     8221 tcgcggtatc attgcagcac tggggccaga tggtaagccc tcccgtatcg tagttatcta 
     8281 cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc 
     8341 ctcactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga 
     8401 tttaaaactt catttttaat ttaaaaggat ctaggtgaag atcctttttg ataatctcat 
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     8461 gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg tcagaccccg tagaaaagat 
     8521 caaaggatct tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa 
     8581 accaccgcta ccagcggtgg tttgtttgcc ggatcaagag ctaccaactc tttttccgaa 
     8641 ggtaactggc ttcagcagag cgcagatacc aaatactgtt cttctagtgt agccgtagtt 
     8701 aggccaccac ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taatcctgtt 
     8761 accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata 
     8821 gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac agcccagctt 
     8881 ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag aaagcgccac 
     8941 gcttcccgaa gggagaaagg cggacaggta tccggtaagc ggcagggtcg gaacaggaga 
     9001 gcgcacgagg gagcttccag ggggaaacgc ctggtatctt tatagtcctg tcgggtttcg 
     9061 ccacctctga cttgagcgtc gatttttgtg atgctcgtca ggggggcgga gcctatggaa 
     9121 aaacgccagc aacgcggcct ttttacggtt cctggccttt tgctggcctt ttgctcacat 
     9181 ggctcgacag atcttcaata ttggccatta gccatattat tcattggtta tatagcataa 
     9241 atcaatattg gctattggcc attgcatacg ttgtatctat atcataatat gtacatttat 
     9301 attggctcat gtccaatatg accgccatgt tggcattgat tattgactag ttattaatag 
     9361 taatcaatta cggggtcatt agttcatagc ccatatatgg agttccgcgt tacataactt 
     9421 acggtaaatg gcccgcctgg ctgaccgccc aacgaccccc gcccattgac gtcaataatg 
     9481 acgtatgttc ccatagtaac gccaataggg actttccatt gacgtcaatg ggtggagtat 
     9541 ttacggtaaa ctgcccactt ggcagtacat caagtgtatc atatgccaag tccgccccct 
     9601 attgacgtca atgacggtaa atggcccgcc tggcattatg cccagtacat gaccttacgg 
     9661 gactttccta cttggcagta catctacgta ttagtcatcg ctattaccat ggtgatgcgg 
     9721 ttttggcagt acaccaatgg gcgtggatag cggtttgact cacggggatt tccaagtctc 
     9781 caccccattg acgtcaatgg gagtttgttt tggcaccaaa atcaacggga ctttccaaaa 
     9841 tgtcgtaata accccgcccc gttgacgcaa atgggcggta ggcgtgtacg gtgggaggtc 
     9901 tatataagca gagctcgttt agtgaaccgt cagatcacta gaagctttat tgcggtagtt 
     9961 tatcacagtt aaattgctaa cgcagtcagt gcttctgaca caacagtctc gaacttaagc 
    10021 tgcagaagtt ggtcgtgagg cactgggcag gtaagtatca aggttacaag acaggtttaa 
    10081 ggagaccaat agaaactggg cttgtcgaga cagagaagac tcttgcgttt ctgataggca 
    10141 cctattggtc ttactgacat ccactttgcc tttctctcca caggtgtcca ctcccagttc 
    10201 aattacagct cttaaggcta gagtacttaa tacgactcac tatagggtcg ac 
// 
Data 3.S1: mlh3 overexpression plasmid seqeuence genBank DNA file 
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tyr 211 sgRNA F caccg ACGGTCATCCACCCCTTTGA 
tyr 184 sgRNA F caccg CTGAGGTCCAGATGGTGCAC 
tyr 136 sgRNA F caccg TCTGCCTGAAAGCTGGCCGC 
tyr 237 sgRNA F cacc GGGTGGATGACCGTGAGTCC 
  tyr 211 sgRNA R aaac TCAAAGGGGTGGATGACCGT c 
tyr 184 sgRNA R aaac GTGCACCATCTGGACCTCAG c 
tyr 136 sgRNA R aaac GCGGCCAGCTTTCAGGCAGA c 
tyr 237 sgRNA R aaac GGACTCACGGTCATCCACCC 
 
Table 3.S1: Primer sequences used in CRISPR/cas9 construct cloning 
These constructs were cloned into the pX458 plasmid created by Feng Zhang for mammalian 
CRISPR/cas9 engineering. 
 
 
tyr F Ill Adapter 
CTCTTTCCCTACACGACGCTCTTCCGATCT  NNNN   
CACCATGGATGGGTGATGGG 
tyr R Ill Adapter 
CTGGAGTTCAGACGTGTGCTCTTCCGATCT  NNNN    
TGAGCACTGGCAGGTCCTAT 
PE PCR F 
AATGATACGGCGACCACCGAGATCTACAC  
TCTTTCCCTACACGACGCTCTTCCGATCT 
PE PCR R 
CAAGCAGAAGACGGCATACGAGAT  XXXXXX  
GTGACTGGAGTTCAGACGTGTGCTCTTCCG 
 
Table 3.S2: Primers used for genomic locus amplification and Illumina sequencing library 
preparation 
The first two primers are the pair used for gDNA amplification of the tyr locus. The last two 
primers are the pair used for the second round of PCR for Illumina library preparation. 
XXXXXX in PE PCR R represents any six bases which can be used for sample indexing, which 
allows for pooling of samples in a single illumine lane. 
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Science is commonly described as a collection of facts. While the scientific body of knowledge 
is important and should be referenced, the core of the scientific method requires creative 
application of these facts to test new hypotheses; in the process we discover more about the 
world and add to the body of knowledge. As Albert Einstein famously said, “Any fool can know. 
The point is to understand.” In this work, I have applied the knowledge of others in new ways to 
better understand the processes underlying fertility and more specifically spermatogenesis.  
I first took the high throughput data on various germ and somatic cell stages, sequencing and 
protein interaction, which were generated by other groups. Using machine learning I was able to 
figure out which ones would be the most informative for differentiating between fertility and 
non-fertility genes. This was then used to produce lists of a few hundred genes which I predict to 
affect various fertility functions like spermatogenesis and oogenesis in both mice and humans. 
With better quality sequencing data for human germ cells and oogenesis stages, I think better 
predictions could be made, but the existing list should be reasonably accurate. 
In order to test some of my predictions I then developed an experimental protocol to screen 
genes for spermatogenesis function in vivo. By transfecting a pool of small hairpin RNA 
expression cassettes into mouse testicular germ cells, I was able to affordably test up to 29 
different genes simultaneously in a month. The performance of this method compares favorably 
to other benchmarked RNAi screens and with minimal adjustments this protocol could be used to 
test up to 300 genes simultaneously in one experiment. Twenty one of the top twenty six 
predicted spermatogenesis genes passed the experimental screen, providing confidence for more 
costly follow-up studies, especially for three genes with unknown molecular function 
(4933411K16Rik, GSG1, and SPATA4). 
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Finally I detail the progress I have made towards using genetic engineering to repair 
dysfunctional spermatogenesis in mice. From the first flawed attempts to overexpress transgenes 
in knockout mice to the current experiments using CRISPR to change genotypes in mouse germ 
cells, I have found various ways to fail in direct in vivo genetic engineering. However those 
failures have provided hints on different approaches to achieve better results which we are 
currently carrying out. 
Most of my projects and research interests lie in taking new technological innovations and using 
them for novel applications. As a result, much of my work would not have been possible without 
the efforts of many other people. Obviously the data and experimental systems developed by 
other groups have been pivotal in inspiring all of the projects that I have described. Less obvious 
contributions have included the comments and mentorship of numerous professors, post-docs, 
and fellow graduate students in helping me understand the various technologies and their 
capabilities and limitations so that I could freely adjust them for my desired application. I hope 
that this work inspires other research projects which will add to the immense and yet insufficient 
body of scientific knowledge. 
“If I have seen further, it is by standing on the shoulders of giants.” – Isaac Newton 
 
